* 590050

TRANSFER RNA, MITOCHONDRIAL, LEUCINE, 1; MTTL1


Alternative titles; symbols

tRNA-LEU, MITOCHONDRIAL, 1


HGNC Approved Gene Symbol: MT-TL1


TEXT

The mitochondrial tRNA for leucine (UUR) is encoded by nucleotides 3230-3304. (In UUR, R = A or G.)


Gene Function

Transcription termination of the mitochondrial genome requires binding of mitochondrial transcription termination factor (MTERF; 602318) to a 13-bp termination sequence (mitochondrial DNA nucleotides 3237 to 3249) located within the tRNA-leu(UUR) gene. Using gel filtration and PCR for repeated selection of bound sequences from a random pool of double-stranded DNA, Nam and Kang (2005) found that MTERF bound a 16-bp consensus sequence containing the 13-bp termination sequence within tRNA-leu(UUR). MTERF bound single-stranded DNA containing this sequence from the mitochondrial light strand, but not the heavy strand. Nam and Kang (2005) hypothesized that preferential binding of MTERF to the light strand may explain its orientation-dependent termination activity.


Biochemical Features

Yakubovskaya et al. (2010) determined the 2.2-angstrom crystal structure of mature human MTERF1 bound to double-stranded DNA (nucleotides 3232 to 3253 of mitochondrial DNA) containing the termination sequence within leu-tRNA(UUR). They found that binding of MTERF1 to the termination sequence unwound the DNA molecule and promoted eversion of 3 nucleotides. Base flipping was critical for stable binding and transcriptional termination.


Molecular Genetics

The uridine in the wobble position of the anticodon of MTTL1 is modified to taurinomethyluridine. Yasukawa et al. (2000) found that MTTL1 containing the 3243A-G (590050.0001) or 3271T-C (590050.0002) mutations, both of which result in MELAS syndrome (540000), lack this modification. They hypothesized that the lack of this modification may lead to the mistranslation of leucine into noncognate phenylalanine codons by the mutant tRNA, according to the mitochondrial wobble rule, and/or a decrease in the rate of mitochondrial protein synthesis. Yasukawa et al. (2000) suggested that the lack of uridine modification may explain why 2 different mutations manifest indistinguishable clinical features.

By molecular surgery of wildtype MTTL1 purified from human placenta, Kirino et al. (2004) created MTTL1 in which the taurinomethyluridine was replaced by unmodified uridine in order to examine the wobble modification deficiency independent of the pathogenic 3243A-G and 3271T-C mutations. Using an in vitro mitochondrial translation system, they demonstrated that the lack of taurinomethyluridine in MTTL1 results in a codon-specific translational deficiency. The tRNA bearing the unmodified wobble uridine showed strong binding to the UUA codon, but only weak binding to the UUG codon. Kirino et al. (2004) concluded that the lack of taurinomethyluridine modification results in an inability of MTTL1 to form codon-anticodon basepairs with UUG, and that the modified wobble uridine plays a functional role in the decoding of UUG codons by stabilizing the U:G wobble basepairing on the ribosomal A site.

From human cytoplasmic hybrids (cybrids) containing 3243A-G tRNA-leu(UUR) mutant or wildtype mitochondria from heteroplasmic MELAS patient myoblasts, Li and Guan (2010) developed a nearly homoplastic mutant cybrid line and an isogenic homoplastic wildtype cybrid line. They found that overexpression of LARS2 (604544) in the mutant cybrid line, but not the wildtype cybrid line, increased the steady-state level of aminoacylated tRNA-leu(UUR) and the rate of RNA processing and translation and restored mitochondrial respiration.


ALLELIC VARIANTS ( 12 Selected Examples):

.0001 MELAS SYNDROME

DIABETES AND DEAFNESS, MATERNALLY INHERITED, INCLUDED
MUSCLE STIFFNESS, PAINFUL, INCLUDED
3-@METHYLGLUTACONIC ACIDURIA, INCLUDED
MACULOPATHY, AGE-RELATED, INCLUDED
CYCLIC VOMITING SYNDROME, INCLUDED
MITOCHONDRIAL COMPLEX IV DEFICIENCY, INCLUDED
MERRF/MELAS OVERLAP SYNDROME, INCLUDED
MTTL1, 3243A-G
  
RCV000010206...

The 3243A-G MTTL1 mutation is the most common heteroplasmic mtDNA mutation associated with disease. The percentage of mutated mtDNA decreases in blood as patients get older (Pyle et al., 2007).

PHENOTYPES

Goto et al. (1990) and Kobayashi et al. (1990) independently reported an mtDNA point mutation associated with the MELAS syndrome (540000). Kobayashi et al. (1991) showed that the A-to-G transition at nucleotide 3243 in the tRNA-leu (UUR) gene was indeed the cause of MELAS. (In UUR, R = A or G.) They isolated, from the same muscle tissue of a patient with MELAS, cell lines with distinctly different phenotypes: one was respiration-deficient and the other was apparently normal. The respiration-deficient cells were found to carry the abnormality in mtDNA. The mutation was found in 8 patients from unrelated families who had the mutation in heteroplasmic form, but was not found in control persons. Enter et al. (1991) likewise found this mutation in heteroplasmic form in Caucasian patients with the MELAS syndrome. This point mutation lies within a DNA segment responsible for transcription termination of the rRNA genes.

By histochemical, immunohistochemical, and single-fiber polymerase chain reaction (PCR) analysis, Moraes et al. (1992) demonstrated that ragged-red fibers in MELAS syndrome were associated with high levels of mutant mitochondrial genomes and with partial cytochrome c oxidase deficiency.

Ciafaloni et al. (1992) found the nucleotide 3243 mutation in 21 of 23 patients with MELAS and in all 11 oligosymptomatic and 12 of 14 asymptomatic relatives, but in only 5 of 50 patients with mitochondrial disease without features of MELAS. The proportion of mutant genomes in muscle ranged from 56 to 95% and was significantly higher in the patients with MELAS than in their oligosymptomatic or asymptomatic relatives. In those in whom both muscle and blood were studied, the percentage of mutations was significantly lower in blood and was not detected in 3 of 12 asymptomatic relatives.

In 2 patients with classic features of MELAS, Lertrit et al. (1992) found the A-to-G base substitution at nucleotide 3243 of tRNA(leu) in one and an 11084A-G mutation of ND4 in the other (516003.0001). The patient with the 3243A-G mutation was a 29-year-old woman with a 2-year history of classic migraine, recurrent stroke-like episodes with bilateral occipital infarction, recurrent occipital seizures, electroencephalogram consistent with encephalopathy, and high lactate and pyruvate levels in blood and cerebrospinal fluid. Muscle biopsy demonstrated extensive ragged-red fibers. Mosewich et al. (1993) studied a large family with the 3243 mutation as the cause of the MELAS syndrome. Family members had various combinations of sensorineural hearing loss, retinal pigmentary degeneration, migraine, hypothalamic hypogonadism, and mild myopathy. Only one member had a stroke-like episode at the age of 46 years. This patient had the highest percentage of mitochondrial chromosomes carrying the point mutation.

Matthews et al. (1994) described a woman without neurologic symptoms who died suddenly at the age of 42 of cardiomyopathy and lactic acidosis. Heteroplasmy for the 3243 mutation was found with a higher proportion of mutant mtDNA in heart (0.49), skeletal muscle (0.56), and liver (0.55) than in other tissues studied, for example, kidney (0.03). Vilarinho et al. (1997) reported a 6-year-old Portuguese boy with dilated cardiomyopathy, lactic acidosis, and no evidence of neurologic abnormality. Molecular genetic analysis showed the 3243 mutation in 88% of total muscle mtDNA and in 68% of the blood mitochondrial genome. Lower percentages were detected in blood from the mother (43%) and brother (49%). The brother had asymptomatic mild hyperlactic acidemia.

In a family of Indonesian descent, de Vries et al. (1994) found that clinical severity of MELAS varied directly in proportion to the quantity of mutated mitochondrial DNA in different tissues. The eldest of 5 children suffered from increasing sensorineural hearing loss after 15 years of age. The third-born sib had severe convulsions at the age of 18 years with stroke-like episodes and lactic acidosis. The fifth-born sib had unusually severe manifestations of MELAS with first manifestations at 7 years of age and death at the age of 14 years from severe cardiomyopathy. The clinically unaffected mother had 35% mutated mtDNA in her muscle but no mutated mtDNA in blood or fibroblasts.

As discussed in 520000, the maternally inherited diabetes-deafness syndrome (MIDD) without the manifestations of MELAS syndrome has been observed in association with an A-to-G transition at nucleotide 3243 in the MTTL1 gene (van den Ouweland et al., 1992). Reardon et al. (1992) and Schulz et al. (1993) described kindreds in which members with the maternally transmitted diabetes-deafness syndrome had an A-to-G transition at nucleotide 3243 of MTTL1.

Manouvrier et al. (1995) observed the 3243A-G mutation in the MTTL1 gene segregating with maternally inherited diabetes mellitus, sensorineural deafness, hypertrophic cardiomyopathy, or renal failure in a large pedigree with 35 affected members in 4 generations. Presenting symptoms almost consistently involved deafness and recurrent attacks of migraine-like headaches, but the clinical course of the disease varied within and across generations. Hypertrophic cardiomyopathy had not previously been a common finding in persons with the 3243A-G mutation and renal failure had not been reported.

Odawara et al. (1995) found the 3243 mutation in 3 of 300 patients with noninsulin-dependent diabetes mellitus or impaired glucose tolerance, and in none of 94 insulin-dependent diabetes mellitus or 115 nondiabetic controls. None of the patients with the mutation had significant sensorineural hearing loss.

Yang et al. (1995) described a 32-year-old Taiwanese woman in whom MELAS syndrome associated with diabetes mellitus and hyperthyroidism was caused by an A-to-G transition at nucleotide 3243 in the MTTL1 gene. In blood cells, approximately 60% of mtDNA was of the mutant type. In Taiwan, Chuang et al. (1995) found the A-to-G mutation at position 3243 in the MTTL1 gene in 1 of 23 pedigrees with multiple sibs affected with NIDDM. The pedigree was consistent with mitochondrial disease in terms of maternal transmission, relatively early onset, nonobesity, insulin-requirement, and association with hearing impairment. There was no correlation between the degree of heteroplasmy of the mitochondrial gene mutations in leukocyte DNA and clinical severity. Thus, the A-to-G transition at nucleotide 3243 is associated with 2 clinically distinct maternally transmitted syndromes: MELAS and noninsulin-dependent diabetes mellitus (NIDDM) with sensorineural hearing loss. In some populations the latter syndrome of maternally-inherited diabetes and deafness may represent 1 to 3% of all cases of NIDDM (Velho et al., 1996).

Yorifuji et al. (1996) reported this mutation in a mother with diabetes mellitus and sensorineural hearing loss and in her son. The clinical picture in the boy included short stature (as a result of deficient growth hormone secretion), moderate mental retardation, progressive nephropathy, and diabetes mellitus. Estimated percentages of mutated mtDNA were 11.8% in the child and 5.1% in the mother. In the renal biopsy specimen from the child, the percentage of mutated mtDNA was 65.6%. Yorifuji et al. (1996) proposed that nephropathy in the child was a result of this mutation. They suggested that mitochondrial disease should be taken into account when a patient has nephropathy of unknown cause.

Morten et al. (1995) sequenced part of the mtDNA control region in 11 unrelated patients heteroplasmic for the 3243 mutation associated with the MELAS phenotype. Only 2 patients shared the same sequence haplotype, implying that the 3243 mutation occurs independently in the maternal lineages of most MELAS patients.

Damian et al. (1996) reported a family in which a female infant with VACTERL (the association of vertebral, anal, cardiovascular, tracheoesophageal, renal, and limb defects; 192350) died at age 1 month due to renal failure. Her mother and sister later developed classic mitochondrial cytopathy associated with the A-to-G point mutation at nucleotide 3243 of mtDNA. Molecular analysis of mtDNA in preserved kidney tissue from the infant with VACTERL demonstrated 100% mutant mtDNA in multicystic and 32% mutant mtDNA in normal kidney tissue. Mild deficiency of complex I respiratory chain enzyme activity was found in the mother's muscle biopsy. Other maternal relatives were healthy but had low levels of mutant mtDNA in blood. Damian et al. (1996) stated that this was the first report to provide a precise molecular basis for a case of VACTERL. Stone and Biesecker (1997) were studying a cohort of 62 patients with VACTERL association. All of the children had normal chromosomes; only 1 had symptoms suggestive of mitochondriopathy, i.e., deafness and muscle weakness. All children had at least 3 of the 6 categories of anomalies associated with VACTERL. None of the affected children had levels of the 3243 mutation that were detectable by the methods used. Stone and Biesecker (1997) recognized the limitations of their study such as heteroplasmy of different tissues (only lymphocytes were studied). Stone and Biesecker (1997) suggested that the proposita reported by Damian et al. (1996) may have had oculoauriculovertebral dysplasia (164210) rather than VACTERL association.

Feigenbaum et al. (1996) also described a family that expanded the extreme clinical variability known to be associated with the A-to-G transition at nucleotide position 3243 of MTTL1. The propositus, a fraternal twin, presented at birth with clinical manifestations consistent with diabetic embryopathy, including anal atresia, caudal dysgenesis, and multicystic dysplastic kidneys. His cotwin, also male, was normal at birth, but at 3 months of age presented with intractable seizures later associated with developmental delay. The twins' mother developed diabetes mellitus type I at the age of 20 years and gastrointestinal problems at 22 years. Since age 19 years, the maternal aunt had had recurrent strokes, seizures, mental deterioration, and deafness, later diagnosed as MELAS syndrome due to the A-to-G mutation. A maternal uncle had diabetes mellitus type I, deafness, and normal intellect, and died at 35 years of age after recurrent strokes. This pedigree raised the possibility that, in some cases, diabetic embryopathy may be due to a mitochondrial cytopathy that affects both the mother's pancreas (and results in diabetes mellitus and the metabolic dysfunction associated with it) and the embryonic/fetal and placental tissues which make the embryo more vulnerable to this insult.

Velho et al. (1996) detected the 3243 mutation in 25 of 50 tested members of 5 white French pedigrees. Mutation-positive family members presented variable clinical features, ranging from normal glucose tolerance to insulin-requiring diabetes. They described the clinical phenotypes of affected members and detailed evaluations of insulin secretion and insulin sensitivity in 7 mutation-positive individuals who had a range of glucose tolerance from normal to impaired to NIDDM. All subjects, including those with normal glucose tolerance, demonstrated abnormal insulin secretion on at least 1 test. The data suggested to Velho et al. (1996) that a defect of glucose-regulated insulin secretion is an early and possible primary abnormality in carriers of the mutation. They speculated that this defect may result from the progressive reduction of oxidative phosphorylation and may implicate the glucose-sensing mechanism of beta cells.

Tamagawa et al. (1997) described the audiologic features in patients with hearing loss associated with the 3243A-G mutation. Four patients without and 5 patients with MELAS were studied. Most of the patients had bilateral progressive sensorineural hearing loss. The most common shape of the audiogram was sloping, while cases in the advanced stages had flat audiograms. Speech discrimination scores were generally poor and did not parallel the degree of hearing loss. The studies suggested that the lesion for hearing loss could include both cochlear and retrocochlear involvement, but did not demonstrate a significant difference in the audiologic findings between patients with and those without MELAS.

Lam et al. (1997) reported the case of a boy in whom MELAS appeared to be precipitated by valproate therapy. He had mild mental retardation and a right-sided convulsion at the age of 12 years. About 1 year later he experienced a similar seizure and was then treated with sodium valproate (200 mg 3 times daily). Eight days after initiation of valproate, he developed right hemiparesis and hypotonia and had 2 seizures. The serum levels of valproate were not excessive, but when no improvement occurred an idiosyncratic drug reaction was suspected and valproate was discontinued. Blood lactate and pyruvate were found to be elevated. Brain CT scan showed a left parietooccipital infarct and bilateral basal ganglia calcification. Muscle biopsy showed ragged-red fibers. Electron microscopy of muscle showed increased numbers of mitochondria and atypical mitochondria in the subsarcolemmal region, some with inclusion bodies. A 3243A-G mutation was detected in mitochondrial DNA from this patient. This mutation predisposed the patient to the detrimental effects of valproate on oxidative phosphorylation. The findings of Lam et al. (1997) supported the suggestion that valproate should not be given to patients suspected of having mitochondrial diseases. In addition, for patients whose seizures worsen with valproate therapy, an inborn error of mitochondrial metabolism should be suspected.

In a 21-year-old male patient with overlapping MELAS and Kearns-Sayre syndrome, Wilichowski et al. (1998) demonstrated the 3243A-G mutation in the MTTL1 gene. Progressive external ophthalmoplegia, pigmentary retinopathy, and right bundle branch block were present when he experienced the first stroke-like episode at 18 years of age. The 3243A-G mutation was found in 79% of mitochondrial DNA and was present at low levels in fibroblasts (49%) and blood cells (37%). Biochemical analysis showed diminished activities of pyruvate dehydrogenase (23%) and respiratory chain complexes I and IV (57%) in muscle, but normal activities in fibroblasts. Immunochemical studies showed normal content of E1-alpha, E1-beta, and E2 proteins. No nuclear mutation of the E1-alpha gene (PDHA1; 300502) was found. These observations suggested that mitochondrial DNA defects may be associated with altered nuclear encoded enzymes that are actively imported into mitochondria and constitute components of the mitochondrial matrix.

Dashe and Boyer (1998) discussed the case of a 13-year-old girl with a relapsing-remitting neurologic disorder that proved to be MELAS. The 3243A-G mitochondrial mutation was identified. The patient had had a normal childhood, although she was awkward at running, bicycle riding, and gymnastics. Twenty-six months before admission, she had an acute febrile episode with otitis, pharyngitis, headache, drowsiness, imbalance, and confusion, and abnormalities of the cerebral cortex were found by MRI and computed tomography (CT). The following month the girl had a grand mal seizure, followed by cortical blindness for 18 hours, with slow resolution. Three sibs of the mother had died in childhood. One, an older brother, never walked and died at 2 years of age of 'Schilder's disease;' another brother died in infancy of a 'high fever;' and a sister died of 'malnutrition' at 4 years of age. Both the proband's mother and a maternal uncle had hearing loss. Disorders causing strokes or stroke-like episodes in children were reviewed, including disorders of blood vessels or blood and metabolic disorders. In this case, analysis of mitochondrial DNA in skeletal muscle and cerebellum showed that 88% of the mitochondrial DNA was mutant. Over a period of 7 or 8 years the patient continued to have seizures that were difficult to control, accompanied by decline in cognition, hearing, vision, and balance. By the age of 20 years, she could no longer walk. Endocrinopathies, including hypothyroidism, inappropriate release of antidiuretic hormone, and diabetes mellitus developed in her late teens. She died with sepsis and multiorgan failure at the age of 23 years.

Chinnery et al. (1998) demonstrated that for both the MELAS 3243A-G mutation and the MERRF 8344A-G mutation (590060.0001) higher levels of mutant mtDNA in the mothers' blood were associated with an increased frequency of affected offspring. They also found that at any one level of maternal mutation load there was a greater frequency of affected offspring for the MELAS 3243A-G mutation than for the MERRF 8344A-G mutation.

Sue et al. (1999) reported 3 unrelated children with the 3243A-G mutation who presented with severe psychomotor delay in early infancy. One patient's clinical picture was more consistent with Leigh syndrome, with apneic episodes, ataxia, and bilateral striatal lesions on brain MRI. A second patient had generalized seizures refractory to treatment and bilateral occipital lesions on brain MRI. The third child had atypical retinal pigmentary changes, seizures, areflexia, and cerebral atrophy on brain MRI. All patients had several atypical features in addition to early onset: absence of an acute or focal neurologic deficit, variable serum and cerebrospinal fluid lactate levels, and lack of ragged-red fibers in muscle biopsy specimens. The proportion of mutant mtDNA in available tissues was relatively low (range, 5 to 51% in muscle and 4 to 39% in blood). The observations extended the phenotypic expression of the 3243A-G 'MELAS' mutation, and confirmed previous observations that there is 'poor correlation between abundance of mutant mtDNA in peripheral tissues and neurologic phenotype.'

Deschauer et al. (1999) detected the 3243A-G mutation heteroplasmatically in DNA from muscle and blood of a 61-year-old patient who at the age of 54 developed a myopathy with painful muscle stiffness as the predominant symptom. Additionally, a hearing impairment requiring a hearing aid for the left ear, numbness of the left arm and leg, and impaired glucose tolerance were present. Nocturnal sleep was severely disturbed by the pain. Neurologic examination showed generalized induration of muscles of the trunk and the upper and lower limbs at rest. Palpation of muscles was painful. On passive motion, there was a contracture-like resistance. A stiff-legged gait was observed, caused by pain and contracture. Muscle histopathology showed a few ragged-red fibers.

Smith et al. (1999) studied 13 subjects with the 3243A-G mutation from 7 different pedigrees with maternally inherited diabetes and deafness to evaluate the association of retinal disease. Visual symptoms, particularly loss of visual acuity, appeared to be infrequent. Test findings suggested that the retinal dystrophy involved defective functioning of retinal pigment epithelial cells and of both rod and cone photoreceptors. The pigmentary retinopathy did not prevent diabetic retinopathy; one subject had evidence of both disorders. The authors stated that the 3243A-G mutation accounts for 0.5 to 2.8% of diabetes.

Latkany et al. (1999) reported the ocular findings in 4 family members with MELAS syndrome caused by the 3243A-G transition in the MTTL1 gene. Findings included ophthalmoplegia, neurosensory deafness, reduced photopic and scotopic electroretinogram (ERG) b-wave amplitudes, myopathy, and slowly progressive geographic macular retinal pigment epithelium atrophy.

Aggarwal et al. (2001) found the same mutation in a 29-year-old woman with gestational diabetes, deafness, Wolff-Parkinson-White (WPW) syndrome (194200), placenta accreta, and premature graying. Premature graying of the hair had started at age 15 years. Placenta accreta is a rare disorder, occurring especially in primigravidae. The features are 'retained placenta' and severe postpartum hemorrhage. The authors claimed this to be the first report of an association of the 3243A-G mtDNA mutation with WPW syndrome; a study of 27 other patients with WPW syndrome failed to reveal this mutation. The patient's sister also suffered from WPW syndrome, premature graying, and sensorineural deafness.

De Kremer et al. (2001) described a child with a 3243A-G mutation of mtDNA in all tissues. The patient had severe failure to thrive, severely delayed gross motor milestones, marked muscle weakness, and dilated cardiomyopathy. He also developed neutropenia at age 4 years. Laboratory studies showed persistently elevated urinary levels of 3-methylglutaconic and 2-ethylhydracrylic acids and low blood levels of cholesterol. The child died at age 4.5 years. De Kremer et al. (2001) suggested that Barth-like syndrome should be added to the list of phenotypes observed with the MELAS mutation.

In Finland, Uimonen et al. (2001) estimated the rate of progression of deafness in patients with the 3243A-G mutation. They examined 14 men and 24 women. The impairment of hearing was worse in men than in women, and women outnumbered men among patients with normal hearing or mild hearing impairment. The rate of progression was calculated to be 2.9 dB per year in men and 1.5 dB per year in women. A high degree of mutant heteroplasmy, male gender, and age were found to increase the severity of hearing impairment.

Deschauer et al. (2001) found the 3243A-G mutation in 16 patients with mitochondrial encephalomyopathies (10 index patients and 6 symptomatic relatives). Only 6 of these patients presented with stroke-like episodes and met the classic criteria of MELAS syndrome. One had MELAS/MERRF overlap syndrome. Two patients presented with stroke-like episodes but did not meet the classic criteria of MELAS. Of the 8 other patients, 1 had myopathy with hearing loss and diabetes mellitus, 1 had chronic progressive external ophthalmoplegia, 1 had diabetes mellitus with hearing loss, 1 had painful muscle stiffness with hearing loss, 1 had cardiomyopathy, 1 had diabetes mellitus, and 2 had hearing loss as predominant features. In 11 of the 16 patients, hearing impairment was obvious on clinical examination. Furthermore, all 5 patients with normal hearing on clinical examination showed subclinical hearing loss.

Chinnery et al. (2001) studied 9 patients from 4 families with the 3243A-G mutation; only 1 of the patients demonstrated severe neurologic disease with a proximal myopathy. Detailed study of resting and active muscle phosphate, creatine, and ATP synthesis failed to show any relationship between mutation load (percentage of mutated mtDNA in the muscle) and mitochondrial function in vivo. The authors suggested that nuclear genetic factors may play a modifying role in mitochondrial dysfunction.

Petruzzella et al. (2004) described cerebellar ataxia as an atypical manifestation of the 3243A-G MELAS mutation. The patient was a 55-year-old man who denied a family history of neurologic diseases and presented a 10-year history of progressive speech and balance disturbances. IQ was not affected. There was mild proximal muscle weakness and hypotrophy in the upper limb girdle muscles. The concurrence of muscle weakness and atrophy raised the suspicion of mitochondrial involvement, prompting testing. The 3243A-G mutation was found in relatively low abundance.

Jones et al. (2004) tested 570 patients with early or late age-related maculopathy (see 603075) for the 3243A-G mutation in mtDNA. Only 1 study participant with early ARM, hypertension, ischemic heart disease, and asthma was found to carry the 3243A-G mutation. Jones et al. (2004) concluded that the 3243A-G mutation is a very rare cause of typical ARM in the general population.

Salpietro et al. (2003) identified the 3243A-G mutation in 4 affected members of an Italian family with cyclic vomiting syndrome (500007). The youngest affected member, a 5-year-old boy, had 70% mutant mtDNA in peripheral blood. The boy's mother, maternal aunt, and maternal grandmother, who were all affected, had 35%, 30%, and 25% mutant mtDNA, respectively. There was a positive correlation between amount of mutant mtDNA and clinical severity. The 3 adults were affected by the syndrome during childhood and developed migraine headaches as adults.

Bohm et al. (2006) identified the 3243A-G mutation in 6 unrelated patients with mitochondrial complex IV deficiency (220110).

Donovan and Severin (2006) reported a kindred in which 4 of 7 sibs had adult-onset diabetes mellitus and sensorineural hearing loss with a confirmed mutation at position 3243 in the tRNA. Two other sibs in this kindred demonstrated different phenotypes of mitochondrial disease. After 1 year of treatment with coenzyme Q10, repeat stress thallium testing demonstrated improvement in the exercise tolerance of the proband from 7 to 12 minutes. Audiometry testing did not demonstrate a change in the rate of hearing decline.

In a study of 51 Danish individuals with the 3243A-G mutation, Jeppesen et al. (2006) found that skeletal muscle mutation load correlated inversely with maximal oxygen update and maximal workload during cycling exercise. Resting venous lactate directly corresponded to muscle mutation load. Those with COX-negative and/or ragged red fibers had over 50% mutation load in muscle, and all those with hearing impairment and diabetes mellitus or hearing impairment alone had more than 65% mutation load. In contrast, mutation load in blood was not correlated, or only weakly correlated, with these parameters. Jeppesen et al. (2006) concluded that the threshold at which oxidative impairment and muscle symptoms occur is as low as 50 to 65% in patients with the 3243A-G mutation, a level that is lower than previously reported based on cell culture studies.

Janssen et al. (2008) defined the 'mitochondrial energy-generating system' (MEGS) capacity as a measurement encompassing mitochondrial enzymatic reactions from oxidation of pyruvate to the export of ATP, which can be used as an indicator for overall mitochondrial function. In an analysis of muscle tissue from 24 MELAS patients with the 3243A-G mutation, MEGS capacity correlated better with mutation load than did analysis of individual respiratory chain enzyme activities, including complex I, III, and IV. The sensitivity and specificity of measurement using MEGS reached 78% and 100%, respectively, for a mitochondriopathy, which was significantly more accurate than measuring individual enzyme activities alone.

In a review of 45 probands with the 3243A-G mutation, Kaufmann et al. (2009) found variable involvement of multiple organ systems. In addition to classic MELAS features, patients had psychiatric problems, hearing loss, diabetes, exercise intolerance, gastrointestinal disorders, short stature, and learning disabilities.

In a patient with MELAS due to the 3243A-G mutation, Costello and Sims (2009) reported safe and effective treatment of symptomatic myoclonus with lamotrigine.

Nakamura et al. (2010) reported a family in which 4 members carried both the 3243A-G mutation and a 8356T-C transition in the MTTK gene (590060.0002), which is usually associated with MERFF syndrome. The female proband and her cousin had MERFF, a deceased aunt had a MERFF/MELAS overlap syndrome, and the mother of the proband was asymptomatic. Genetic analysis showed that the double mutations were heteroplasmic in blood of the proband and her cousin but at low levels in her asymptomatic mother. In muscle tissue of the proband and her aunt, the proportion of the 3243A-G mutation was higher than in blood, and the 8356T-C mutation was homoplasmic. Nakamura et al. (2010) hypothesized that the phenotype in affected individuals began with MERFF and evolved into MELAS later in life.

In a questionnaire-based survey, Parsons et al. (2010) found that 28 (80%) of 35 patients with MELAS due to the 3243A-G mutation and 33 (62%) of 53 carrier relatives reported autonomic symptoms compared to 2 (12%) of 16 controls. Gastrointestinal symptoms, orthostatic dizziness, and cold or discolored hands and feet were the most common complaints among mutation carriers.

In a retrospective study, Malfatti et al. (2013) found that 38 of 41 individuals with the MTTL1 c.3243A-G mutation had symptoms consistent with MELAS, whereas 3 were asymptomatic. Cardiac investigations identified left ventricular hypertrophy and/or left ventricular dysfunction in 18 patients, along with Wolff-Parkinson-White syndrome in 7, conduction system disease in 4, and atrial fibrillation in 1. Over a median 5-year follow-up period, 11 patients died, including 3 due to heart failure. Malfatti et al. (2013) concluded that, after central neurologic disease, cardiac disease has the greatest impact on prognosis in patients with the c.3243A-G mutation. Left ventricular hypertrophy was the only independent prognostic risk factor for adverse cardiac events, suggesting that these patients should be closely monitored. The severity of cardiac disease and adverse events did not correlate with mutation load in blood or urine or with ragged-red fibers on muscle biopsy.

STUDIES OF THE 3243A-G MUTATION

Yoneda et al. (1992) studied the growth characteristics of cells carrying the MELAS mitochondrial mutation by introducing patient mitochondria into human mtDNA-less cells. Five of 13 clonal cell lines containing mixtures of wildtype and mutant mtDNAs were found to undergo a rapid shift of their genotype toward the pure mutant type. On the other hand, the other 8 cell lines, which included 6 exhibiting nearly homoplasmic mutant mtDNA, maintained a stable genotype. Subcloning experiments and growth rate measurements clearly indicated that an intracellular replicative advantage of mutant mtDNA was mainly responsible for the dramatic shift toward the mutant genotype observed in the unstable cell lines.

Matthews et al. (1995) showed that fibroblast clones from subjects heteroplasmic for the MELAS 3243A-G mutation show wide variability in the degree of heteroplasmy. The distribution of mutant mtDNA between different cells was not random about the mean, suggesting that selection against cells with high proportions of mutant mtDNA had occurred. To explore the way in which heteroplasmic mtDNA segregates in mitosis, they followed the distribution of heteroplasmy between clones over approximately 15 generations. There was either no change or a decrease in the variance of intercellular heteroplasmy for the MELAS 3243A-G mutation, which was considered most consistent with segregation of heteroplasmic units of multiple mtDNA molecules in mitosis. After mitochondria from one of the MELAS 3243A-G fibroblast cultures were transferred to a mitochondrial DNA-free cell line derived from osteosarcoma cells by cytoplast fusion, the mean level and intercellular distribution of heteroplasmy was unchanged. Matthews et al. (1995) interpreted the findings as evidence that somatic segregation (rather than nuclear background or cell differentiation state) is the primary determinant of the level of heteroplasmy.

Janssen et al. (1999) showed that cells harboring patient-derived mitochondria with an A-to-G transition at nucleotide position 3243 display severe loss of respiration. Despite the low level of leucyl-tRNA-Leu(UUR), the rate of mitochondrial translation was not seriously affected by this mutation. Therefore, a decrease of mitochondrial protein synthesis as such did not appear to be a necessary prerequisite for loss of respiration. Rather, the mitochondrially encoded proteins seemed subject to elevated degradation, leading to a severe reduction in their steady state levels. The results were interpreted as favoring a scheme in which the 3243 mutation causes loss of respiration through accelerated protein degradation, leading to a disequilibrium between the levels of mitochondrial and nuclear encoded respiratory chain subunits and thereby a reduction of functional respiratory chain complexes.

Borner et al. (2000) used an assay that combined tRNA oxidation and circularization to determine the relative amounts and states of aminoacylation of mutant and wildtype tRNAs in tissue samples from MELAS and MERRF (545000) patients. In most, but not all, biopsies from MELAS patients carrying the 3243A-G substitution, the mutant tRNA was underrepresented among processed and/or aminoacylated tRNAs. In contrast, in biopsies from MERRF patients harboring the 8344A-G substitution in the tRNA-lys gene (590060) neither the relative abundance nor the aminoacylation of the mutated tRNA was affected. The authors concluded that whereas the 3243A-G mutation may contribute to the pathogenesis of MELAS by reducing the amount of aminoacylated tRNA-leu, the 8344A-G mutation does not affect tRNA-lys function in MERRF patients in the same way.

Chomyn et al. (2000) presented several lines of evidence indicating that the protein synthesis defect in 3243A-G MELAS mutation-carrying cells is mainly due to a reduced association of mRNA with ribosomes, possibly as a consequence of the tRNA-leu(UUR) aminoacylation defect.

In a longitudinal study, Olsson et al. (2001) determined the proportion of the mitochondrial 3243A-G mutation in DNA obtained from cervical smear samples collected from 3 patients with maternally inherited diabetes and deafness. The proportion of mtDNA with the 3243A-G mutation decreased over time in the samples from all 3 patients: in patient 1 the mutant mtDNA decreased from 32 to 10% in 18 years, in patient 2 from 11 to 5% in 8 years, and in patient 3 from 26 to 19% in 4 years. This corresponded to a relative annual decline of 5.8% of the initial heteroplasmy level. The authors suggested that the observed decrease in mutational load with time was probably the consequence of negative selection acting against high levels of mutation load either at the level of cells or mitochondria due to impairment of the oxidative phosphorylation. The results may explain the observation of molecular genetic anticipation seen in some pedigrees with mitochondrial disorders. The percentage level of mutant mtDNA may be higher in the recent generation compared to the preceding one simply because the samplings were made on individuals of different ages in the pedigree.

The amount of 3243A-G heteroplasmy in blood tends to slowly decrease over time. Rahman et al. (2001) compared the levels of 3243A-G mutant mtDNA in blood at birth from Guthrie cards and at the time of diagnosis in a blood DNA sample from patients with MELAS syndrome. Paired blood DNA samples separated by 9 to 19 years were obtained from 6 patients. Quantification of mutant load demonstrated a decline (range 12 to 29%) in the proportion of mutant mtDNA in all cases. These results suggested that mutant mtDNA is slowly selected from rapidly dividing blood cells in MELAS. The authors showed that in elderly patients false-negative results may be obtained in testing for mitochondrial diseases when DNA from leukocytes is used. They proposed muscle and hair follicles as a better source of DNA.

Nam and Kang (2005) found that the 3243A-G mutation reduced, but did not eliminate, binding of recombinant human MTERF to the tRNA-leu(UUR) termination sequence.

Pyle et al. (2007) established an accurate fluorescent assay for 3243A-G heteroplasmy and the amount of mtDNA in blood with real-time PCR. The amount of mutated and wildtype mtDNA was measured at 2 time points in 11 subjects. The percentage of mutated mtDNA decreased exponentially during life, and peripheral blood leukocytes in patients harboring 3243A-G were profoundly depleted of mtDNA. A similar decrease in mtDNA had been seen in other mitochondrial disorders, and in 3243A-G cell lines in culture, indicating that depletion of mtDNA may be a common secondary phenomenon in several mitochondrial diseases. Thus, depletion of mtDNA is not always due to mutation of a nuclear gene involved in mtDNA maintenance.

Durham et al. (2007) showed that segments of human skeletal muscle fibers harboring 2 pathogenic mtDNA mutations retain normal cytochrome c oxidase (COX) activity by maintaining a minimum amount of wildtype mtDNA. For these mutations, direct measurements of mutated and wildtype mtDNA molecules within the same skeletal muscle fiber are consistent with the 'maintenance of wildtype' hypothesis, which predicts that there is nonselective proliferation of mutated and wildtype mtDNA in response to the molecular defect. However, for the 3243A-G mutation, a superabundance of wildtype mtDNA was found in many muscle fiber sections with negligible COX activity, indicating that the pathogenic mechanism for this particular mutation involves interference with the function of the wildtype mtDNA or wildtype gene products.

Using an anti-complex IV immunocapture technique and mass spectrometry, Janssen et al. (2007) found that COX I and COX II existed exclusively with the correct amino acid sequences in 3243A-G cells. The findings excluded a dominant-negative effect of the 3243A-G mutation, leaving tissue-specific accumulation by mtDNA segregation as the most likely cause of variable mitochondrial disease expression in patients with this mutation.

Rajasimha et al. (2008) observed an exponential decrease of mutant 3243A-G mtDNA in blood over time by simulating the segregation of the mutation in hematopoietic stem cells and leukocyte precursors. The findings were consistent with a selective process acting at the stem cell level and could explain why the level of mutant mtDNA in blood is almost always lower than that observed in nondividing tissues such as skeletal muscle. From human data (Rahman et al., 2001; Pyle et al., 2007), Rajasimha et al. (2008) derived a formula to correct for the change in heteroplasmy over time. The findings indicated that there is selection against pathogenic mtDNA in stem cells but not in committed blood cell precursors. The mechanism of loss of stem cells with high mutation levels was sufficient to explain the data, but other mechanisms may also be involved.

Sasarman et al. (2008) analyzed myoblasts isolated from a MELAS patient who was homoplasmic for the 3243A-G mutation. MELAS myoblasts showed only moderately affected translation of mitochondrial proteins, but an almost complete lack of assembly of respiratory chain complexes I, IV, and V. Pulse-chase labeling showed reduced stability of all mitochondrial translation products consistent with an assembly defect. There was also evidence of amino acid misincorporation in 3 polypeptides: MTCO3 (516050), MTCO2 (516040), and ATP6 (516060). The assembly defect could be partially rescued by overexpression of mitochondrial translation elongation factors EFTu (TUFM; 602389) or EFG2 (GFM2; 606544). The data indicated that the 3243A-G mutation produces both loss- and gain-of-function phenotypes, explaining the apparent discrepancy between the severity of the translation and respiratory chain assembly defects.

Yakubovskaya et al. (2010) identified 3243A as 1 of 3 nucleotides in leu-tRNA(UUR) that was everted during MTERF1 binding. The 3243A-G mutation reduced the affinity of MTERF1 binding to leu-tRNA(UUR).

Dvorakova et al. (2016) reported the comprehensive clinical phenotype of 50 Czech patients with the m.3243A-G mutation. Symptoms developed in 33 patients (66%) and 17 carriers remained unaffected (34%). The age of onset varied from 1 month to 47 years of age, with juvenile presentation occurring in 53% of patients. Myopathy was the most common presenting symptom (18%), followed by CPEO/ptosis and hearing loss, with the latter also being the most common second symptom. Stroke-like episodes occurred in 14 patients, although never as a first symptom, and were frequently preceded by migraines (58%). Rhabdomyolysis developed in 2 patients. The second symptom appeared 5.0 +/- 8.3 years (range 0-28 years) after the first, and the interval between the second and third symptom was 2.0 +/- 6.0 years (range 0-21 years). Four patients remained monosymptomatic up to 12 years of follow-up. The sequence of symptoms according to their time of manifestation was migraines, myopathy, seizures, CPEO/ptosis, stroke-like episodes, hearing loss, and diabetes mellitus. The average age at death was 32.4 +/- 17.7 years (range 9-60 years) in the juvenile form and 44.0 +/- 12.7 years (range 35-53 years) in the adult form. Some patients with stroke-like episodes harbored very low heteroplasmy levels in various tissues. No threshold for any organ dysfunction could be determined based on these levels.

POPULATION GENETICS

In an adult population of 245,201 individuals, Majamaa et al. (1998) studied the frequency of the 3243A-G mutation. In addition, they ascertained 615 patients with diabetes mellitus, sensorineural hearing impairment, epilepsy, occipital brain infarct, ophthalmoplegia, cerebral white matter disease, basal ganglia calcifications, hypertrophic cardiomyopathy, or ataxia, and examined 480 samples for the mutation. The mutation was found in 11 pedigrees, and its frequency was calculated to be 16.3/100,000 in the adult population. As determined by mtDNA haplotyping, the mutation had arisen in the population at least 9 times. Clinical evaluation of the probands revealed a syndrome that most frequently consisted of hearing impairment, cognitive decline, and short stature. The high prevalence of the common MELAS mutation in the adult population suggested that mitochondrial disorders constitute one of the largest diagnostic categories of neurogenetic diseases.

The low frequency of deleterious point mutations in mtDNA in human populations has suggested that they are under strong negative selection, and a reduced genetic fitness of mutation carriers had been assumed (Zeviani et al., 1998). In a population-based study of the 3243A-G mutation in the province of Oulu, Finland (Majamaa et al., 1998), Moilanen and Majamaa (2001) calculated the net reproduction rate for 31 mutation carriers and found it to be similar to that of the general population. The average fertility of mutation carriers was not reduced, and the generation time was not different between the mutation carriers and the general population. Moilanen and Majamaa (2001) stated that morbidity and mortality from the mutation may have changed compared to that of historical populations (e.g., diabetes mellitus may have proved fatal in earlier times but is now treatable). Moilanen and Majamaa (2001) concluded that the low frequency of this mutation in populations may still be explained by a mild uniform selection or a selection that depends on the degree of the mutant mtDNA heteroplasmy; alternatively, there may be no host-level selection at all, implying that other factors are responsible for the low population frequency.

Among 230 patients with sensorineural hearing loss in otorhinolaryngology clinics in Japan, Nagata et al. (2001) found 4 instances of the 3243A-G mutation (1.74%). Association of maternally inherited diabetes mellitus, cardiomyopathy, a family history of possible maternal inheritance of sensorineural hearing loss, and an onset of sensorineural hearing loss between the teenage years and the forties were signs suggesting the mutation.

Using high-resolution restriction fragment length polymorphism analysis and control-region sequencing, Torroni et al. (2003) studied 35 mtDNAs from Spain that harbored the 3243A-G mutation in association with either MELAS or a wide array of disease phenotypes. A total of 34 different haplotypes were found, indicating that all instances of the 3243A-G mutation are probably due to independent mutational events. Haplotypes were distributed into 13 haplogroups whose frequencies were close to those of the general Spanish population. Moreover, there was no statistically significant difference in haplogroup distribution between patients with MELAS and those with disease phenotypes other than MELAS. Torroni et al. (2003) concluded that the 3243A-G mutation may harbor all the evolutionary features expected from a severely deleterious mtDNA mutation under strong negative selection, and they reveal that European mtDNA backgrounds do not play a substantial role in modulating the mutation's phenotypic expression.

Uusimaa et al. (2007) estimated the prevalence of the 3243A-G mutation in northern Finland to be 18.4 in 100,000 children. The most common clinical manifestations appearing in childhood were sensorineural hearing loss, short stature or delayed maturation, migraine, learning difficulties, and exercise intolerance. Segregation analyses did not show a correlation between mother and child heteroplasmy, arguing against the random drift hypothesis.

Elliott et al. (2008) determined the frequency of 10 mitochondrial point mutations in 3,168 neonatal cord blood samples from sequential live births in North Cumbria in England, analyzing matched maternal blood samples to estimate the de novo mutation rate. Mitochondrial DNA mutations were detected in 15 offspring (0.54%, 95% confidence interval = 0.30-0.89%). Of these live births, 0.00107% (95% confidence interval = 0.00087-0.0127) harbored a mutation not detected in the mother's blood, providing an estimate of the de novo mutation rate. The most common mutation was mitochondrial 3243A-G. Elliott et al. (2008) concluded that at least 1 in 200 healthy humans harbors a pathogenic mitochondrial DNA mutation that potentially causes disease in the offspring of female carriers.


.0002 MELAS SYNDROME

MTTL1, 3271T-C
  
RCV000010212...

In 3 of 40 MELAS (540000) patients, Goto et al. (1991) found a T-to-C transition at nucleotide position 3271 in the mitochondrial tRNA-leu (UUR) gene. The change was very near the site of the most common mutation at 3243 (590050.0001). Hayashi et al. (1993) introduced mitochondrial DNA with the T3271C mutation into HeLa cells lacking mtDNA and showed that accumulation of more than 87% of the mutant form in the cybrid clones induced both low complex I activity and abnormal mtDNA-encoded polypeptide synthesis that included at least subunit ND6 of complex I.

Stenqvist et al. (2005) identified a heteroplasmic 3271T-C mutation in a patient with MELAS who died at age 18 years. The mutation was present in 90% of fibroblasts and 94% skeletal muscle. Stenqvist et al. (2005) stated that 7 to 15% of MELAS patients have the 3271T-C mutation.


.0003 MERRF SYNDROME

DIABETES MELLITUS, NONINSULIN-DEPENDENT, MATERNALLY TRANSMITTED
MTTL1, 3256C-T
  
RCV000010213...

In a patient with a neurologic syndrome resembling MERRF (myoclonus epilepsy and ragged-red fibers) plus optic neuropathy, retinopathy, and diabetes, Moraes et al. (1993) found a C-to-T transition at position 3256 within the mitochondrial tRNA-leu (UUR) gene. The patient was heteroplasmic for this mutation, with higher percentages of mutant mtDNA in affected tissues, and undetectable levels in maternal relatives. Analysis of single muscle fibers indicated that morphologic and biochemical alterations appeared only when the proportion of mutant mtDNA exceeded 90% of the total cellular mtDNA pool. Moraes et al. (1993) indicated that this was the ninth known mutation in the tRNA-leu (UUR) gene and suggested that this region is an 'etiologic hotspot' (not necessarily a mutation hotspot) in mitochondrial disease.

Hirai et al. (1998) studied a mitochondrial DNA mutation in a 45-year-old Japanese woman with noninsulin-dependent diabetes mellitus and muscle atrophy. They identified a mitochondrial DNA C-to-T heteroplasmic mutation at nucleotide position 3256. The mutation was located in a conserved region of the MTTL1 gene. Eight other members of her family were examined for the mutation. Six of them had the same mutation together with noninsulin-dependent diabetes mellitus, and 1 teenaged boy had the mutation and impaired glucose tolerance. The other family member who did not have the mutation had normal glucose tolerance. The enzyme activity of the mitochondrial oxidative phosphorylation pathway in the muscle of the proband was decreased, especially in complex I. The authors concluded that the mutation may be responsible for the abnormal glucose metabolism. No mention of deafness was made.


.0004 CARDIOMYOPATHY WITH OR WITHOUT SKELETAL MYOPATHY

MTTL1, 3303C-T
  
RCV000010215...

Silvestri et al. (1994) described a C-to-T transition at nucleotide 3303 of mtDNA in 7 members of a family with cardiomyopathy and myopathy. The proband and 2 sibs had fatal infantile cardiomyopathy, whereas in 3 maternal relatives the disease manifested later in life as sudden cardiac death or as mitochondrial myopathy with cardiomyopathy. The mutation was homoplasmic in all tissues (including blood) from the proband and her brother, but heteroplasmic in blood from 5 oligosymptomatic or asymptomatic maternal relatives. The mutation disrupted a conserved basepair in the aminoacyl stem of the tRNA-leu (UUR).

The causative role of the 3303C-T mutation in the MTTL1 gene was confirmed by Bruno et al. (1999), who found the mutation in 8 patients from 4 unrelated families. In the first family, the clinical presentation was infantile cardiomyopathy; in the second family, proximal limb and neck weakness dominated the clinical picture for the first 10 years of life, when cardiac dysfunction became apparent; in the third family, 2 individuals presented with isolated skeletal myopathy and 2 others with skeletal myopathy and cardiomyopathy; in the fourth family, 1 patient had fatal infantile cardiomyopathy and the other had a combination of skeletal myopathy and cardiomyopathy.


.0005 ENCEPHALOMYOPATHY, MITOCHONDRIAL

MTTL1, 3252A-G
  
RCV000010217...

In a patient with mitochondrial encephalomyopathy, pigmentary retinopathy, dementia, hypoparathyroidism, and diabetes mellitus, Morten et al. (1993) found heteroplasmy in blood (30%) and muscle (76%) for a mutation at nucleotide 3252 in the MTTL1 gene. In the proband, mental retardation was first noted at the age of 4 years. She came to medical attention at the age of 11 with recurrent vomiting attributed to hiatus hernia. Mitochondrial encephalomyopathy was diagnosed at the age of 13 when she presented with frequent falls and increasing weakness. Muscle biopsy demonstrated 3% ragged red fibers, rising to 5 to 10% 7 years later. She went on to develop diabetes mellitus in her mid-teens, and cerebral atrophy was demonstrated by CT scan. By the age of 31, she had also developed hypoparathyroidism, worsening dementia, and pigmentary retinopathy, and her spastic paraparesis had progressed. She died of complete heart block, aspiration pneumonia, and renal failure at the age of 31 years. The mother, who had the mutation in 50% of muscle cells, developed progressive generalized weakness with spastic paraparesis and dysarthria when she was 44 years old. Muscle biopsy demonstrated 10% ragged red fibers. She died at the age of 58 years following a stroke-like episode. The maternal grandmother had difficulty walking and frequent falls from age 60 which was attributed to cerebellar degeneration. A sister of the proposita died suddenly of 'myocarditis' at the age of 7. Although she had no known neurologic or developmental impairment, there had been a longstanding renal problem. The A-to-G transition at nucleotide 3252 was located at a highly conserved position in the tRNA molecule, close to the 3243 mutation which is associated with more than 80% of MELAS cases.


.0006 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, PROXIMAL MYOPATHY, AND SUDDEN DEATH

MTTL1, 3251A-G
  
RCV000010218...

Sweeney et al. (1993) reported a family exhibiting maternal inheritance of a variable syndrome comprising ocular, neck, and proximal upper limb weakness, psychiatric features, and sudden death. Of 15 definitely or probably affected individuals, 7 had died in early adult life, probably of respiratory failure. All living affected members of the family showed an A-to-G transition at nucleotide 3251 of the MTTL1 gene.

In a girl who died at age 14 from a rapidly progressive mitochondrial myopathy, Houshmand et al. (1996) found heteroplasmy for the A3251G mutation. A large proportion of muscle fibers contained accumulations of abnormal mitochondria but no cytochrome c oxidase deficient fibers were present. Studies of isolated muscle mitochondria revealed a profound isolated complex I deficiency. A high percentage of mutant mtDNA was found in muscle (94%), fibroblasts (93%), brain (90%), liver (80%), and heart (79%). The family was not available for investigation. The proportion of mutant mtDNA was 28% in normal-appearing fibers and 61% in abnormal fibers. The patient had been healthy until age 10 years when she had insidious onset of gastrointestinal symptoms with diarrhea, nausea, fatigue, and tachycardia on mild physical exertion. Terminally, in the last years of life she developed persistent tachycardia, lactic acidosis, and hypercapnia, and in the last month of life, cardiorespiratory failure.


.0007 CARDIOMYOPATHY WITH OR WITHOUT SKELETAL MYOPATHY

MTTL1, 3260A-G
  
RCV000010219...

Mariotti et al. (1994) studied a 23-year-old man, subject III-1 in the report by Zeviani et al. (1991), who suffered from heart failure and muscle weakness due to skeletal myopathy with ragged-red fibers. He had signs of congestive heart failure. Densitometric quantitation showed that 90% of mtDNA extracted from skeletal muscle was mutant. A point mutation in the MTTL1 gene was shown to be an A-to-G transition at nucleotide position 3260. The disorder was of adult onset and inherited from the mother. From study of respiratory capacity and mitochondrial protein synthesis in transformant cybrids harboring the mutation, Mariotti et al. (1994) proved that the G3260 mutation was responsible for the clinical disorder in this family. They recommended the transformant cybrid system for evaluating the pathogenic potential of mtDNA mutations.


.0008 SKELETAL MYOPATHY, RESPONSIVE TO RIBOFLAVIN

MTTL1, 3250T-C
  
RCV000010216...

Ogle et al. (1997) reported the case of a young girl with complex I deficiency and skeletal myopathy who had a sustained clinical response to riboflavin during 3 years of therapy. She had been noted from the age of 13 months to hold her head in the flexed position when walking. At 2 years of age, she required assistance with standing from the seated position, frequently complained of tiredness after walking short distances, and often stumbled. There was severe weakness of neck extensors, but she could extend her head against gravity. There was marked lumbar lordosis, mild proximal weakness, a mild decrease in tone peripherally, and normal deep tendon reflexes. Muscle bulk was normal. There was no ptosis, ophthalmoplegia, or hepatosplenomegaly. Molecular studies found no mutations in the putative flavin mononucleotide binding site in the 51-kD subunit of complex I, but a T-to-C transition at nucleotide 3250 was identified in the MTTL1 gene. The mutation was present in a heteroplasmic state. The same mutation had been reported by Goto et al. (1992) in a family with 5 members who had fatigue with or without muscle weakness. There were also 5 sibs in this family who had died in early childhood of unknown causes. In the family reported by Ogle et al. (1997), 2 other infants died a SIDS (272120)-like death.


.0009 SUDDEN INFANT DEATH SYNDROME

MTTL1, 3290T-C
  
RCV000010220...

Opdal et al. (1999) investigated the MTTL1 gene and the first part of the MTND1 gene (516000) in 158 cases of sudden infant death syndrome (SIDS; 272120) and 97 controls. The basepairs in the range of 3230 to 3330 were investigated using PCR and temporal temperature gradient electrophoresis (TTGE). If a band shift was detected by TTGE, the area was investigated and the D-loop was sequenced. Three different point mutations (3290T-C in the MTTL1 gene, and 3308T-C (516000.0007) and 3308T-G (516000.0008)in the MTND1 gene) were detected in 4 of the SIDS cases, while none of the controls was mutated. They also found a high D-loop substitution rate in these 4 cases. Opdal et al. (1999) suggested that the findings indicated that mtDNA mutations may play a role in some cases of SIDS. They pointed out that a 3250T-C mutation in the MTTL1 gene (590050.0008) had been detected in a family in which a sister of the proband and a maternal uncle died of SIDS, and that a 3303C-T mutation in the MTTL1 gene (590050.0004) had been detected in a family in which an older brother of the proband died of SIDS.


.0010 NEUROPSYCHIATRIC DISORDER AND EARLY-ONSET CATARACT

MTTL1, 3274A-G
  
RCV000010221...

Jaksch et al. (2001) reported a patient with a novel heteroplasmic 3274A-G mutation in the MTTL1 gene, who suffered from a neuropsychiatric disorder and early-onset cataract associated with severe deficiency of respiratory complex I in skeletal muscle. The patient was normal until age 12, when his performance in school declined. At age 27, he developed acute psychotic symptoms, depression, and suicidal thoughts. Bilateral hearing loss, gait instability, and bilateral dysdiadochokinesis were also noted. At that time, brain MRI showed cerebral and cerebellar atrophy and ventricular enlargement. Bilateral cataracts were found at age 30. At age 33 bilateral vision loss and tapetoretinal degeneration were noted. Changes on brain MRI were progressive. The heteroplasmic 3274A-G mutation was found in skeletal muscle (25%) but not in white blood cells of the patient.


.0011 RECLASSIFIED - VARIANT OF UNKNOWN SIGNIFICANCE

MTTL1, 3249G-A
  
RCV000010222

This variant, formerly titled KEARNS-SAYRE SYNDROME, has been reclassified as a variant of unknown signficance because its pathogenicity has not been confirmed.

Seneca et al. (2001) reported a male patient with clinical signs suggestive of Kearns-Sayre syndrome (530000), including onset at age 22 years of progressive visual failure with retinopathy, external ophthalmoplegia, sensorineural hearing loss, exercise intolerance, muscle weakness, and difficulty swallowing. Skeletal muscle analysis showed decreased activity of complex I and numerous ragged-red fibers. A heteroplasmic 3249G-A point mutation was found in the MTTL1 gene, with a high percentage of mutant mtDNA in skeletal muscle (85%) and in leukocytes (45%). The patient's mother carried less than 5% mutant mtDNA in her blood.

Yakubovskaya et al. (2010) found that 3249G formed a double hydrogen bond with arg387 of MTERF1 (602318). The 3249G-A mutation eliminated this interaction and significantly interfered with transcriptional termination by MTERF1.


.0012 MYELODYSPLASTIC SYNDROME, SOMATIC

MTTL1, 3242G-A
  
RCV000010223...

Ultrastructural abnormalities seen in mitochondria of bone marrow cells of patients with myelodysplastic syndrome (MDS), such as pathologic iron accumulation in the mitochondria of erythroblasts, suggest that mitochondrial dysfunction may contribute to the pathophysiology of MDS. In a 65-year-old male patient with refractory anemia with excess blasts (RAEB), Gattermann et al. (2004) identified a novel somatic mutation of the mitochondrial MTTL1 gene, 3242G-A. Heteroduplex analysis indicated that 40 to 50% of mitochondrial DNA molecules in the bone marrow carried the mutation. The mutation was not detectable by heteroduplex analysis in the peripheral blood. However, peripheral blood CD34+ cells showed the mutation with a proportion of approximately 50%. In hematopoietic colony assays, CD34+ cells from bone marrow and peripheral blood yielded only colonies with wildtype mtDNA; this result indicated that the mtDNA mutation in CD34+ cells was associated with a maturation defect. Mitochondrial tRNA mutations impair mitochondrial protein synthesis, thereby causing dysfunction of the mitochondrial respiratory chain. Gattermann et al. (2004) suggested that this effect contributed to ineffective hematopoiesis in the patient.

Yakubovskaya et al. (2010) found that 3242G interacted with arg251 of MTERF1 (602318) and that the 3242G-A mutation profoundly reduced transcriptional termination by MTERF1.


REFERENCES

  1. Aggarwal, P., Gill-Randall, R., Wheatley, T., Buchalter, M. B., Metcalfe, J., Alcolado, J. C. Identification of mtDNA mutation in a pedigree with gestational diabetes, deafness, Wolff-Parkinson-White syndrome and placenta accreta. Hum. Hered. 51: 114-116, 2001. [PubMed: 11096278, related citations] [Full Text]

  2. Bohm, M., Pronicka, E., Karczmarewicz, E., Pronicki, M., Piekutowska-Abramczuk, D., Sykut-Cegielska, J., Mierzewska, H., Hansikova, H., Vesela, K., Tesarova, M., Houstkova, H., Houstek, J., Zeman, J. Retrospective, multicentric study of 180 children with cytochrome c oxidase deficiency. Pediat. Res. 59: 21-26, 2006. [PubMed: 16326995, related citations] [Full Text]

  3. Borner, G. V., Zeviani, M., Tiranti, V., Carrara, F., Hoffmann, S., Gerbitz, K. D., Lochmuller, H., Pongratz, D., Klopstock, T., Melberg, A., Holme, E., Paabo, S. Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients. Hum. Molec. Genet. 9: 467-475, 2000. [PubMed: 10699170, related citations] [Full Text]

  4. Bruno, C., Kirby, D. M., Koga, Y., Garavaglia, B., Duran, G., Santorelli, F. M., Shield, L. K., Xia, W., Shanske, S., Goldstein, J. D., Iwanaga, R., Akita, Y., Carrara, F., Davis, A., Zeviani, M., Thorburn, D. R., DiMauro, S. The mitochondrial DNA C3303T mutation can cause cardiomyopathy and/or skeletal myopathy. J. Pediat. 135: 197-202, 1999. [PubMed: 10431114, related citations] [Full Text]

  5. Chinnery, P. F., Howell, N., Lightowlers, R. N., Turnbull, D. M. MELAS and MERRF: the relationship between maternal mutation load and the frequency of clinically affected offspring. Brain 121: 1889-1894, 1998. [PubMed: 9798744, related citations] [Full Text]

  6. Chinnery, P. F., Taylor, D. J., Manners, D., Styles, P., Lodi, R. No correlation between muscle A3243G mutation load and mitochondrial function in vivo. Neurology 56: 1101-1104, 2001. [PubMed: 11320187, related citations] [Full Text]

  7. Chomyn, A., Enriquez, J. A., Micol, V., Fernandez-Silva, P., Attardi, G. The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNA-leu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes. J. Biol. Chem. 275: 19198-19209, 2000. [PubMed: 10858457, related citations] [Full Text]

  8. Chuang, L.-M., Wu, H.-P., Chiu, K. C., Lai, C.-S., Tai, T.-Y., Lin, B. J. Mitochondrial gene mutations in familial non-insulin-dependent diabetes mellitus in Taiwan. Clin. Genet. 48: 251-254, 1995. [PubMed: 8825603, related citations] [Full Text]

  9. Ciafaloni, E., Ricci, E., Shanske, S., Moraes, C. T., Silvestri, G., Hirano, M., Simonetti, S., Angelini, C., Donati, M. A., Garcia, C., Martinuzzi, A., Mosewich, R., Servidei, S., Zammarchi, E., Bonilla, E., DeVivo, D. C., Rowland, L. P., Schon, E. A., DiMauro, S. MELAS: clinical features, biochemistry, and molecular genetics. Ann. Neurol. 31: 391-398, 1992. [PubMed: 1586140, related citations] [Full Text]

  10. Costello, D. J., Sims, K. B. Efficacy of lamotrigine in disabling myoclonus in a patient with an mtDNA A3243G mutation. Neurology 72: 1279-1280, 2009. [PubMed: 19349610, related citations] [Full Text]

  11. Damian, M. S., Seibel, P., Schachenmayr, W., Reichmann, H., Dorndorf, W. VACTERL with the mitochondrial NP 3243 point mutation. Am. J. Med. Genet. 62: 398-403, 1996. [PubMed: 8723071, related citations] [Full Text]

  12. Dashe, J. F., Boyer, P. J. A 13-year-old girl with a relapsing-remitting neurologic disorder (CPC). New Eng. J. Med. 339: 1914-1923, 1998. [PubMed: 9874606, related citations] [Full Text]

  13. De Kremer, R. D., Paschini-Capra, A., Bacman, S., Argarana, C., Civallero, G., Kelley, R. I., Guelbert, N., Latini, A., de Halac, I. N., Giner-Ayala, A., Johnston, J., Proujansky, R., Gonzalez, I., Depetris-Boldini, C., Oller-Ramirez, A., Angaroni, C., Theaux, R. A., Hliba, E., Juaneda, E. Barth's syndrome-like disorder: a new phenotype with a maternally inherited A3243G substitution of mitochondrial DNA (MELAS mutation). Am. J. Med. Genet. 99: 83-93, 2001. [PubMed: 11241464, related citations] [Full Text]

  14. de Vries, D., de Wijs, I., Ruitenbeek, W., Begeer, J., Smit, P., Bentlage, H., van Oost, B. Extreme variability of clinical symptoms among sibs in a MELAS family correlated with heteroplasmy for the mitochondrial A324G mutation. J. Neurol. Sci. 124: 77-82, 1994. [PubMed: 7931425, related citations] [Full Text]

  15. Deschauer, M., Muller, T., Wieser, T., Schulte-Mattler, W., Kornhuber, M., Zierz, S. Hearing impairment is common in various phenotypes of the mitochondrial DNA A3243G mutation. Arch. Neurol. 58: 1885-1888, 2001. [PubMed: 11708999, related citations] [Full Text]

  16. Deschauer, M., Wieser, T., Neudecker, S., Lindner, A., Zierz, S. Mitochondrial 3243 A-to-G mutation (MELAS mutation) associated with painful muscle stiffness. Neuromusc. Disord. 9: 305-307, 1999. [PubMed: 10407850, related citations] [Full Text]

  17. Donovan, L. E., Severin, N. E. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J. Clin. Endocr. Metab. 91: 4737-4742, 2006. [PubMed: 17018649, related citations] [Full Text]

  18. Durham, S. E., Samuels, D. C., Cree, L. M., Chinnery, P. F. Normal levels of wild-type mitochondrial DNA maintain cytochrome c oxidase activity for two pathogenic mitochondrial DNA mutations but not for m.3243A-G. Am. J. Hum. Genet. 81: 189-195, 2007. [PubMed: 17564976, images, related citations] [Full Text]

  19. Dvorakova, V., Kolarova, H., Magner, M., Tesarova, M., Hansikova, H., Zeman, J., Honzik, T. The phenotypic spectrum of fifty Czech m.3243A-G carriers. Molec. Genet. Metab. 118: 288-295, 2016. [PubMed: 27296531, related citations] [Full Text]

  20. Elliott, H. R., Samuels, D. C., Eden, J. A., Relton, C. L., Chinnery, P. F. Pathogenic mitochondrial DNA mutations are common in the general population. Am. J. Hum. Genet. 83: 254-260, 2008. [PubMed: 18674747, related citations] [Full Text]

  21. Enter, C., Muller-Hocker, J., Zierz, S., Kurlemann, G., Pongratz, D., Forster, C., Obermaier-Kusser, B., Gerbitz, K.-D. A specific point mutation in the mitochondrial genome of Caucasians with MELAS. Hum. Genet. 88: 233-236, 1991. [PubMed: 1684568, related citations] [Full Text]

  22. Feigenbaum, A., Chitayat, D., Robinson, B., MacGregor, D., Myint, T., Arbus, G., Nowaczyk, M. J. M. The expanding clinical phenotype of the tRNA-leu(UUR) A-to-G mutation at np 3243 of mitochondrial DNA: diabetic embryopathy associated with mitochondrial cytopathy. Am. J. Med. Genet. 62: 404-409, 1996. [PubMed: 8723072, related citations] [Full Text]

  23. Gattermann, N., Wulfert, M., Junge, B., Germing, U., Haas, R., Hofhaus, G. Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome. Blood 103: 1499-1502, 2004. [PubMed: 14576046, related citations] [Full Text]

  24. Goto, Y., Nonaka, I., Horai, S. A mutation in the tRNA-leu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348: 651-653, 1990. [PubMed: 2102678, related citations] [Full Text]

  25. Goto, Y., Nonaka, I., Horai, S. A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Biochim. Biophys. Acta 1097: 238-240, 1991. [PubMed: 1932147, related citations] [Full Text]

  26. Goto, Y., Tojo, M., Tohyama, J., Horai, S., Nonaka, I. A novel point mutation in the mitochondrial tRNA-Leu(UUR) gene in a family with mitochondrial myopathy. Ann. Neurol. 31: 672-675, 1992. [PubMed: 1514779, related citations] [Full Text]

  27. Hayashi, J.-I., Ohta, S., Takai, D., Miyabayashi, S., Sakuta, R., Goto, Y., Nonaka, I. Accumulation of mtDNA with a mutation at position 3271 in tRNA-leu(UUR) gene introduced from a MELAS patient to HeLa cells lacking mtDNA results in progressive inhibition of mitochondrial respiratory function. Biochem. Biophys. Res. Commun. 197: 1049-1055, 1993. [PubMed: 8280119, related citations] [Full Text]

  28. Hirai, M., Suzuki, S., Onoda, M., Hinokio, Y., Hirai, A., Ohtomo, M., Chiba, M., Kasuga, S., Hirai, S., Satoh, Y., Akai, H., Miyabayashi, S., Toyota, T. Mitochondrial deoxyribonucleic acid 3256C-T mutation in a Japanese family with noninsulin-dependent diabetes mellitus. J. Clin. Endocr. Metab. 83: 992-994, 1998. [PubMed: 9506761, related citations] [Full Text]

  29. Houshmand, M., Larsson, N.-G., Oldfors, A., Tulinius, M., Holme, E. Fatal mitochondrial myopathy, lactic acidosis, and complex I deficiency associated with a heteroplasmic A-to-G mutation at position 3251 in the mitochondrial tRNA-leu(UUR) gene. Hum. Genet. 97: 269-273, 1996. [PubMed: 8786060, related citations] [Full Text]

  30. Jaksch, M., Lochmuller, H., Schmitt, F., Volpel, B., Obermaier-Kusser, B., Horvath, R. A mutation in mt tRNAleu(UUR) causing a neuropsychiatric syndrome with depression and cataract. Neurology 57: 1930-1931, 2001. [PubMed: 11723298, related citations] [Full Text]

  31. Janssen, A. J. M., Schuelke, M., Smeitink, J. A. M., Trijbels, F. J. M., Sengers, R. C. A., Lucke, B., Wintjes, L. T. M., Morava, E., van Engelen, B. G. M., Smits, B. W., Hol, F. A., Siers, M. H., ter Laak, H., van der Knaap, M. S., van Spronsen, F. J., Rodenburg, R. J. T., van den Heuvel, L. P. Muscle 3243A-G mutation load and capacity of the mitochondrial energy-generating system. Ann. Neurol. 63: 473-481, 2008. [PubMed: 18306232, related citations] [Full Text]

  32. Janssen, G. M. C., Hensbergen, P. J., van Bussel, F. J., Balog, C. I. A., Maassen, J. A., Deelder, A. M., Raap, A. K. The A3243G tRNA(Leu(UUR)) mutation induces mitochondrial dysfunction and variable disease expression without dominant negative acting translational defects in complex IV subunits at UUR codons. Hum. Molec. Genet. 16: 2472-2481, 2007. [PubMed: 17656376, related citations] [Full Text]

  33. Janssen, G. M. C., Maassen, J. A., van den Ouweland, J. M. W. The diabetes-associated 3243 mutation in the mitochondrial tRNA-Leu(UUR) gene causes severe mitochondrial dysfunction without a strong decrease in protein synthesis rate. J. Biol. Chem. 274: 29744-29748, 1999. [PubMed: 10514449, related citations] [Full Text]

  34. Jeppesen, T. D., Schwartz, M., Frederiksen, A. L., Wibrand, F., Olsen, D. B., Vissing, J. Muscle phenotype and mutation load in 51 persons with the 3243A-G mitochondrial DNA mutation. Arch. Neurol. 63: 1701-1706, 2006. [PubMed: 17172609, related citations] [Full Text]

  35. Jones, M., Mitchell, P., Wang, J. J., Sue, C. MELAS A3243G mitochondrial DNA mutation and age related maculopathy. Am. J. Ophthal. 138: 1051-1053, 2004. [PubMed: 15629304, related citations] [Full Text]

  36. Kaufmann, P., Engelstad, K., Wei, Y., Kulikova, R., Oskoui, M., Battista, V., Koenigsberger, D. Y., Pascual, J. M., Sano, M., Hirano, M., DiMauro, S., Shungu, D. C., Mao, X., De Vivo, D. C. Protean phenotypic features of the A3243G mitochondrial DNA mutation. Arch. Neurol. 66: 85-91, 2009. [PubMed: 19139304, related citations] [Full Text]

  37. Kirino, Y., Yasukawa, T., Ohta, S., Akira, S., Ishihara, K., Watanabe, K., Suzuki, T. Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease. Proc. Nat. Acad. Sci. 101: 15070-15075, 2004. [PubMed: 15477592, images, related citations] [Full Text]

  38. Kobayashi, Y., Momoi, M. Y., Tominaga, K., Momoi, T., Nihei, K., Yanagisawa, M., Kagawa, Y., Ohta, S. A point mutation in the mitochondrial tRNA-leu (UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). Biochem. Biophys. Res. Commun. 173: 816-822, 1990. [PubMed: 2268345, related citations] [Full Text]

  39. Kobayashi, Y., Momoi, M. Y., Tominaga, K., Shimoizumi, H., Nihei, K., Yanagisawa, M., Kagawa, Y., Ohta, S. Respiration-deficient cells are caused by a single point mutation in the mitochondrial tRNA-leu (UUR) gene in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Am. J. Hum. Genet. 49: 590-599, 1991. [PubMed: 1715668, related citations]

  40. Lam, C. W., Lau, C. H., Williams, J. C., Chan, Y. W., Wong, L. J. C. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Europ. J. Pediat. 156: 562-564, 1997. [PubMed: 9243242, related citations] [Full Text]

  41. Latkany, P., Ciulla, T. A., Cucchillo, P., Malkoff, M. D. Mitochondrial maculopathy: geographic atrophy of the macula in the MELAS associated A to G 3243 mitochondrial DNA point mutation. Am. J. Ophthal. 128: 112-114, 1999. [PubMed: 10482110, related citations] [Full Text]

  42. Lertrit, P., Noer, A. S., Jean-Francois, M. J. B., Kapsa, R., Dennett, X., Thyagarajan, D., Lethlean, K., Byrne, E., Marzuki, S. A new disease-related mutation for mitochondrial encephalopathy lactic acidosis and strokelike episodes (MELAS) syndrome affects the ND4 subunit of the respiratory complex I. Am. J. Hum. Genet. 51: 457-468, 1992. [PubMed: 1323207, related citations]

  43. Li, R., Guan, M.-X. Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the tRNA(Leu(UUR)) A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes. Molec. Cell. Biol. 30: 2147-2154, 2010. Note: Erratum: Molec. Cell. Biol. 37: e00335-17, 2017. [PubMed: 20194621, images, related citations] [Full Text]

  44. Majamaa, K., Moilanen, J. S., Uimonen, S., Remes, A. M., Salmela, P. I., Karppa, M., Majamaa-Voltti, K. A. M., Rusanen, H., Sorri, M., Peuhkurinen, K. J., Hassinen, I. E. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am. J. Hum. Genet. 63: 447-454, 1998. [PubMed: 9683591, related citations] [Full Text]

  45. Malfatti, E., Laforet, P., Jardel, C., Stojkovic, T., Behin, A., Eymard, B., Lombes, A., Benmalek, A., Becane, H.-M., Berber, N., Meune, C., Duboc, D., Wahbi, K. High risk of severe cardiac adverse events in patients with mitochondrial m.3243A-G mutation. Neurology 80: 100-105, 2013. [PubMed: 23243073, related citations] [Full Text]

  46. Manouvrier, S., Rotig, A., Hannebique, G., Gheerbrandt, J.-D., Royer-Legrain, G., Munnich, A., Parent, M., Grunfeld, J.-P., Largilliere, C., Lombes, A., Bonnefont, J.-P. Point mutation of the mitochondrial tRNA(leu) gene (A 3243 G) in maternally inherited hypertrophic cardiomyopathy, diabetes mellitus, renal failure, and sensorineural deafness. J. Med. Genet. 32: 654-656, 1995. [PubMed: 7473662, related citations] [Full Text]

  47. Mariotti, C., Tiranti, V., Carrara, F., Dallapiccola, B., DiDonato, S., Zeviani, M. Defective respiratory capacity and mitochondrial protein synthesis in transformant cybrids harboring the tRNA-leu(UUR) mutation associated with maternally inherited myopathy and cardiomyopathy. J. Clin. Invest. 93: 1102-1107, 1994. [PubMed: 8132749, related citations] [Full Text]

  48. Matthews, P. M., Brown, R. M., Morten, K., Marchington, D., Poulton, J., Brown, G. Intracellular heteroplasmy for disease-associated point mutations in mtDNA: implications for disease expression and evidence for mitotic segregation of heteroplasmic units of mtDNA. Hum. Genet. 96: 261-268, 1995. [PubMed: 7649539, related citations] [Full Text]

  49. Matthews, P. M., Hopkin, J., Brown, R. M., Stephenson, J. B. P., Hilton-Jones, D., Brown, G. K. Comparison of the relative levels of the 3243 (A-to-G) mtDNA mutation in heteroplasmic adult and fetal tissues. J. Med. Genet. 31: 41-44, 1994. [PubMed: 8151636, related citations] [Full Text]

  50. Moilanen, J. S., Majamaa, K. Relative fitness of carriers of the mitochondrial DNA mutation 3243A-G. Europ. J. Hum. Genet. 9: 59-62, 2001. [PubMed: 11175302, related citations] [Full Text]

  51. Moraes, C. T., Ciacci, F., Bonilla, E., Jansen, C., Hirano, M., Rao, N., Lovelace, R. E., Rowland, L. P., Schon, E. A., DiMauro, S. Two novel pathogenic mitochondrial DNA mutations affecting organelle number and protein synthesis: is the tRNA-leu(UUR) gene an etiologic hot spot? J. Clin. Invest. 92: 2906-2915, 1993. [PubMed: 8254046, related citations] [Full Text]

  52. Moraes, C. T., Ricci, E., Bonilla, E., DiMauro, S., Schon, E. A. The mitochondrial tRNA-leu(UUR) mutation in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS): genetic, biochemical, and morphological correlations in skeletal muscle. Am. J. Hum. Genet. 50: 934-949, 1992. [PubMed: 1315123, related citations]

  53. Morten, K. J., Cooper, J. M., Brown, G. K., Lake, B. D., Pike, D., Poulton, J. A new point mutation associated with mitochondrial encephalomyopathy. Hum. Molec. Genet. 2: 2081-2087, 1993. [PubMed: 8111377, related citations] [Full Text]

  54. Morten, K. J., Poulton, J., Sykes, B. Multiple independent occurrence of the 3243 mutation in mitochondrial tRNA-leu(UUR) in patients with the MELAS phenotype. Hum. Molec. Genet. 4: 1689-1691, 1995. [PubMed: 8541865, related citations] [Full Text]

  55. Mosewich, R. K., Donat, J. R., DiMauro, S., Ciafaloni, E., Shanske, S., Erasmus, M., George, D. The syndrome of mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes presenting without stroke. Arch. Neurol. 50: 275-278, 1993. [PubMed: 8442706, related citations] [Full Text]

  56. Nagata, H., Kumahara, K., Tomemori, T., Arimoto, Y., Isoyama, K., Yoshida, K., Konno, A. Frequency and clinical features of patients with sensorineural hearing loss associated with the A3243G mutation of the mitochondrial DNA in otorhinolaryngic clinics. J. Hum. Genet. 46: 595-599, 2001. [PubMed: 11587074, related citations] [Full Text]

  57. Nakamura, M., Yabe, I., Sudo, A., Hosoki, K., Yaguchi, H., Saitoh, S., Sasaki, H. MERRF/MELAS overlap syndrome: a double pathogenic mutation in mitochondrial tRNA genes. J. Med. Genet. 47: 659-664, 2010. [PubMed: 20610441, related citations] [Full Text]

  58. Nam, S.-C., Kang, C. DNA light-strand preferential recognition of human mitochondria transcription termination factor mTERF. J. Biochem. Molec. Biol. 38: 690-694, 2005. [PubMed: 16336784, related citations] [Full Text]

  59. Odawara, M., Sasaki, K., Yamashita, K. Prevalence and clinical characterization of Japanese diabetes mellitus with an A-to-G mutation at nucleotide 3243 of the mitochondrial tRNA-leu(UUR) gene. J. Clin. Endocr. Metab. 80: 1290-1294, 1995. [PubMed: 7714102, related citations] [Full Text]

  60. Ogle, R. F., Christodoulou, J., Fagan, E., Blok, R. B., Kirby, D. M., Seller, K. L., Dahl, H.-H. M, Thorburn, D. R. Mitochondrial myopathy with tRNA-Leu(UUR) mutation and complex I deficiency responsive to riboflavin. J. Pediat. 130: 138-145, 1997. [PubMed: 9003864, related citations] [Full Text]

  61. Olsson, C., Johnsen, E., Nilsson, M., Wilander, E., Syvanen, A.-C., Lagerstrom-Fermer, M. The level of mitochondrial mutation A3243G decreases upon ageing in epithelial cells from individuals with diabetes and deafness. Europ. J. Hum. Genet. 9: 917-921, 2001. [PubMed: 11840193, related citations] [Full Text]

  62. Opdal, S. H., Rognum, T. O., Torgersen, H., Vege, A. Mitochondrial DNA point mutations detected in four cases of sudden infant death syndrome. Acta Paediat. 88: 957-960, 1999. [PubMed: 10519336, related citations] [Full Text]

  63. Parsons, T., Weimer, L., Engelstad, K., Linker, A., Battista, V., Wei, Y., Hirano, M., Dimauro, S., De Vivo, D. C., Kaufmann, P. Autonomic symptoms in carriers of the m.3243A-G mitochondrial DNA mutation. Arch. Neurol. 67: 976-979, 2010. [PubMed: 20697048, related citations] [Full Text]

  64. Petruzzella, V., Zoccolella, S., Amati, A., Torraco, A., Lamberti, P., Carnicella, F., Serlenga, L., Papa, S. Cerebellar ataxia as atypical manifestation of the 3243A-G MELAS function. (Letter) Clin. Genet. 65: 64-65, 2004. [PubMed: 15032978, related citations] [Full Text]

  65. Pyle, A., Taylor, R. W., Durham, S. E., Deschauer, M., Schaefer, A. M., Samuels, D. C., Chinnery, P. F. Depletion of mitochondrial DNA in leucocytes harbouring the 3243A-G mtDNA mutation. (Letter) J. Med. Genet. 44: 69-74, 2007. [PubMed: 16950816, images, related citations] [Full Text]

  66. Rahman, S., Poulton, J., Marchington, D., Suomalainen, A. Decrease of 3243 A-G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. Am. J. Hum. Genet. 68: 238-240, 2001. [PubMed: 11085913, related citations] [Full Text]

  67. Rajasimha, H. K., Chinnery, P. F., Samuels, D. C. Selection against pathogenic mtDNA mutations in a stem cell population leads to the loss of the 3243A-G mutation in blood. Am. J. Hum. Genet. 82: 333-343, 2008. [PubMed: 18252214, images, related citations] [Full Text]

  68. Reardon, W., Ross, R. J. M., Sweeney, M. G., Luxon, L. M., Pembrey, M. E., Harding, A. E., Trembath, R. C. Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA. Lancet 340: 1376-1379, 1992. [PubMed: 1360090, related citations] [Full Text]

  69. Salpietro, C. D., Briuglia, S., Merlino, M. V., Di Bella, C., Rigoli, L. A mitochondrial DNA mutation (A3243G mtDNA) in a family with cyclic vomiting. Europ. J. Pediat. 162: 727-728, 2003. [PubMed: 12905015, related citations] [Full Text]

  70. Sasarman, F., Antonicka, H., Shoubridge, E. A. The A3243G tRNALeu(UUR) MELAS mutation causes amino acid misincorporation and a combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2. Hum. Molec. Genet. 17: 3697-3707, 2008. [PubMed: 18753147, related citations] [Full Text]

  71. Schulz, J. B., Klockgether, T., Dichgans, J., Seibel, P., Reichmann, H. Mitochondrial gene mutations and diabetes mellitus. (Letter) Lancet 341: 438-439, 1993. [PubMed: 8094200, related citations]

  72. Seneca, S., Verhelst, H., de Meirleir, L., Meire, F., Ceuterick-de Groote, C., Lissens, W., van Coster, R. A new mitochondrial point mutation in the transfer RNA-leu gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome. Arch. Neurol. 58: 1113-1118, 2001. [PubMed: 11448301, related citations] [Full Text]

  73. Silvestri, G., Santorelli, F. M., Shanske, S., Whitley, C. B., Schimmenti, L. A., Smith, S. A., DiMauro, S. A new mtDNA mutation in the tRNA-leu(UUR) gene associated with maternally inherited cardiomyopathy. Hum. Mutat. 3: 37-43, 1994. [PubMed: 7906985, related citations] [Full Text]

  74. Smith, P. R., Bain, S. C., Good, P. A., Hattersley, A. T., Barnett, A. H., Gibson, J. M., Dodson, P. M. Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness caused by the mitochondrial DNA 3243 tRNA(leu) A-to-G mutation. Ophthalmology 106: 1101-1108, 1999. [PubMed: 10366077, related citations] [Full Text]

  75. Stenqvist, L., Paetau, A., Valanne, L., Suomalainen, A., Pihko, H. A juvenile case of MELAS with T3271C mitochondrial DNA mutation. Pediat. Res. 58: 258-262, 2005. [PubMed: 16006433, related citations] [Full Text]

  76. Stone, D. L., Biesecker, L. G. Mitochondrial NP 3243 point mutation is not a common cause of VACTERL association. (Letter) Am. J. Med. Genet. 72: 237-238, 1997. [PubMed: 9382149, related citations]

  77. Sue, C. M., Bruno, C., Andreu, A. L., Cargan, A., Mendell, J. R., Tsao, C.-Y., Luquette, M., Paolicchi, J., Shanske, S., DiMauro, S., De Vivo, D. C. Infantile encephalopathy associated with the MELAS A3243G mutation. J. Pediat. 134: 696-700, 1999. [PubMed: 10356136, related citations] [Full Text]

  78. Sweeney, M. G., Bundey, S., Brockington, M., Poulton, K. R., Winer, J. B., Harding, A. E. Mitochondrial myopathy associated with sudden death in young adults and a novel mutation in the mitochondrial DNA leucine transfer RNA(UUR) gene. Quart. J. Med. 86: 709-713, 1993. [PubMed: 8265770, related citations]

  79. Tamagawa, Y., Kitamura, K., Hagiwara, H., Ishida, T., Nishizawa, M., Saito, T., Iwamoto, Y. Audiologic findings in patients with a point mutation at nucleotide 3,243 of mitochondrial DNA. Ann. Otol. Rhinol. Laryng. 106: 338-342, 1997. [PubMed: 9109727, related citations] [Full Text]

  80. Torroni, A., Campos, Y., Rengo, C., Sellitto, D., Achilli, A., Magri, C., Semino, O., Garcia, A., Jara, P., Arenas, J., Scozzari, R. Mitochondrial DNA haplogroups do not play a role in the variable phenotypic presentation of the A3243G mutation. Am. J. Hum. Genet. 72: 1005-1012, 2003. [PubMed: 12612863, related citations] [Full Text]

  81. Uimonen, S., Moilanen, J. S., Sorri, M., Hassinen, I. E., Majamaa, K. Hearing impairment in patients with 3243A-G mtDNA mutation: phenotype and rate of progression. Hum. Genet. 108: 284-289, 2001. [PubMed: 11379873, related citations] [Full Text]

  82. Uusimaa, J., Moilanen, J. S., Vainionpaa, L., Tapanainen, P., Lindholm, P., Nuutinen, M., Lopponen, T., Maki-Torkko, E., Rantala, H., Majamaa, K. Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A-G mutation in children. Ann. Neurol. 62: 278-287, 2007. [PubMed: 17823937, related citations] [Full Text]

  83. van den Ouweland, J. M. W., Lemkes, H. H. P. J., Ruitenbeek, W., Sandkuijl, L. A., de Vijlder, M. F., Struyvenberg, P. A. A., van de Kamp, J. J. P., Maassen, J. A. Mutation in mitochondrial tRNA(leu-UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nature Genet. 1: 368-371, 1992. [PubMed: 1284550, related citations] [Full Text]

  84. Velho, G., Byrne, M. M., Clement, K., Sturis, J., Pueyo, M. E., Blanche, H., Vionnet, N., Fiet, J., Passa, P., Robert, J.-J., Polonsky, K. S., Froguel, P. Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNA Leu(UUR) gene mutation. Diabetes 45: 478-487, 1996. [PubMed: 8603770, related citations] [Full Text]

  85. Vilarinho, L., Santorelli, F. M., Rosas, M. J., Tavares, C., Melo-Pires, M., DiMauro, S. The mitochondrial A3243G mutation presenting as severe cardiomyopathy. J. Med. Genet. 34: 607-609, 1997. [PubMed: 9222976, related citations] [Full Text]

  86. Wilichowski, E., Korenke, G. C., Ruitenbeek, W., De Meirleir, L., Hagendorff, A., Janssen, A. J. M., Lissens, W., Hanefeld, F. Pyruvate dehydrogenase complex deficiency and altered respiratory chain function in a patient with Kearns-Sayre/MELAS overlap syndrome and A3243G mtDNA mutation. J. Neurol. Sci. 157: 206-213, 1998. [PubMed: 9619647, related citations] [Full Text]

  87. Yakubovskaya, E., Mejia, E., Byrnes, J., Hambardjieva, E., Garcia-Diaz, M. Helix unwinding and base flipping enable human MTERF1 to terminate mitochondrial transcription. Cell 141: 982-993, 2010. [PubMed: 20550934, images, related citations] [Full Text]

  88. Yang, C.-Y., Lam, H.-C., Lee, H.-C., Wei, Y.-H., Lu, C.-C., Han, T.-M., Tsai, J.-L., Chuang, Y.-H., Lee, J.-K. MELAS syndrome associated with diabetes mellitus and hyperthyroidism: a case report from Taiwan. Clin. Endocr. 43: 235-239, 1995. [PubMed: 7554321, related citations] [Full Text]

  89. Yasukawa, T., Suzuki, T., Suzuki, T., Ueda, T., Ohta, S., Watanabe, K. Modification defect at anticodon wobble nucleotide of mitochondrial tRNAs-Leu(UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. J. Biol. Chem. 275: 4251-4257, 2000. [PubMed: 10660592, related citations] [Full Text]

  90. Yoneda, M., Chomyn, A., Martinuzzi, A., Hurko, O., Attardi, G. Marked replicative advantage of human mtDNA carrying a point mutation that causes the MELAS encephalomyopathy. Proc. Nat. Acad. Sci. 89: 11164-11168, 1992. [PubMed: 1454794, related citations] [Full Text]

  91. Yorifuji, T., Kawai, M., Momoi, T., Sasaki, H., Furusho, K., Muroi, J., Shimizu, K., Takahashi, Y., Matsumura, M., Nambu, M., Okuno, T. Nephropathy and growth hormone deficiency in a patient with mitochondrial tRNA-leu(UUR) mutation. J. Med. Genet. 33: 621-622, 1996. [PubMed: 8818955, related citations] [Full Text]

  92. Zeviani, M., Gellera, C., Antozzi, C., Rimoldi, M., Morandi, L., Villani, F., Tiranti, V., DiDonato, S. Maternally inherited myopathy and cardiomyopathy: association with mutation in mitochondrial DNA tRNA-leu(UUR). Lancet 338: 143-147, 1991. [PubMed: 1677065, related citations] [Full Text]

  93. Zeviani, M., Tiranti, V., Piantadosi, C. Mitochondrial disorders. Medicine 77: 59-72, 1998. [PubMed: 9465864, related citations] [Full Text]


Ada Hamosh - updated : 12/08/2016
Cassandra L. Kniffin - updated : 12/29/2014
Patricia A. Hartz - updated : 9/19/2013
Patricia A. Hartz - updated : 4/17/2012
Cassandra L. Kniffin - updated : 1/21/2011
Cassandra L. Kniffin - updated : 11/23/2010
Cassandra L. Kniffin - updated : 8/24/2010
Cassandra L. Kniffin - updated : 11/11/2009
Cassandra L. Kniffin - updated : 9/2/2009
Cassandra L. Kniffin - updated : 4/6/2009
Cassandra L. Kniffin - updated : 3/12/2009
Ada Hamosh - updated : 9/8/2008
Cassandra L. Kniffin - updated : 4/17/2008
Cassandra L. Kniffin - updated : 1/15/2008
John A. Phillips, III - updated : 11/7/2007
Cassandra L. Kniffin - updated : 9/28/2007
Victor A. McKusick - updated : 8/8/2007
Cassandra L. Kniffin - updated : 5/30/2007
Victor A. McKusick - updated : 2/21/2007
Cassandra L. Kniffin - updated : 2/20/2006
Cassandra L. Kniffin - updated : 10/17/2005
Jane Kelly - updated : 2/28/2005
Patricia A. Hartz - updated : 1/13/2005
Jane Kelly - updated : 1/12/2005
Victor A. McKusick - updated : 4/16/2004
Victor A. McKusick - updated : 2/25/2004
Ada Hamosh - updated : 5/9/2003
Cassandra L. Kniffin - updated : 12/4/2002
Michael B. Petersen - updated : 8/20/2002
Cassandra L. Kniffin - updated : 6/4/2002
Victor A. McKusick - updated : 1/8/2002
Victor A. McKusick - updated : 12/21/2001
Victor A. McKusick - updated : 10/30/2001
Victor A. McKusick - updated : 5/7/2001
Michael B. Petersen - updated : 4/27/2001
Sonja A. Rasmussen - updated : 4/3/2001
Victor A. McKusick - updated : 2/14/2001
Victor A. McKusick - updated : 1/24/2001
Victor A. McKusick - updated : 8/31/2000
George E. Tiller - updated : 4/14/2000
Victor A. McKusick - updated : 2/1/2000
Victor A. McKusick - updated : 1/31/2000
Victor A. McKusick - updated : 12/15/1999
Victor A. McKusick - updated : 10/25/1999
Victor A. McKusick - updated : 10/13/1999
Victor A. McKusick - updated : 8/5/1999
Victor A. McKusick - updated : 2/20/1999
Victor A. McKusick - updated : 1/7/1999
Victor A. McKusick - updated : 9/11/1998
Victor A. McKusick - updated : 8/26/1998
John A. Phillips, III - updated : 8/21/1998
Victor A. McKusick - updated : 3/24/1998
Michael J. Wright - updated : 12/18/1997
Victor A. McKusick - updated : 9/5/1997
Victor A. McKusick - updated : 7/11/1997
Victor A. McKusick - updated : 6/21/1997
Iosif W. Lurie - updated : 9/17/1996
Creation Date:
Victor A. McKusick : 3/2/1993
carol : 10/20/2023
carol : 04/13/2023
alopez : 04/25/2022
carol : 09/11/2017
alopez : 12/08/2016
alopez : 09/23/2016
carol : 01/13/2015
mcolton : 12/29/2014
ckniffin : 12/29/2014
mgross : 9/19/2013
carol : 9/17/2013
carol : 11/12/2012
mgross : 5/14/2012
terry : 4/17/2012
carol : 6/8/2011
wwang : 2/16/2011
ckniffin : 1/21/2011
wwang : 11/29/2010
ckniffin : 11/23/2010
wwang : 9/16/2010
ckniffin : 8/24/2010
ckniffin : 8/23/2010
wwang : 12/3/2009
ckniffin : 11/11/2009
wwang : 9/9/2009
ckniffin : 9/2/2009
wwang : 4/13/2009
ckniffin : 4/6/2009
wwang : 3/24/2009
ckniffin : 3/12/2009
alopez : 9/17/2008
terry : 9/8/2008
wwang : 4/23/2008
ckniffin : 4/17/2008
wwang : 1/31/2008
ckniffin : 1/15/2008
alopez : 11/7/2007
wwang : 10/4/2007
ckniffin : 9/28/2007
alopez : 8/24/2007
terry : 8/8/2007
wwang : 6/6/2007
ckniffin : 5/30/2007
alopez : 2/26/2007
terry : 2/21/2007
carol : 2/1/2007
alopez : 1/12/2007
wwang : 3/1/2006
ckniffin : 2/20/2006
carol : 10/19/2005
ckniffin : 10/17/2005
terry : 8/3/2005
terry : 4/21/2005
terry : 4/6/2005
tkritzer : 2/28/2005
mgross : 1/13/2005
tkritzer : 1/12/2005
tkritzer : 10/15/2004
ckniffin : 7/15/2004
alopez : 4/20/2004
alopez : 4/20/2004
terry : 4/16/2004
tkritzer : 2/26/2004
terry : 2/25/2004
cwells : 5/13/2003
terry : 5/9/2003
cwells : 12/10/2002
ckniffin : 12/4/2002
alopez : 8/20/2002
carol : 6/17/2002
ckniffin : 6/4/2002
carol : 5/9/2002
carol : 1/9/2002
carol : 1/8/2002
terry : 1/8/2002
alopez : 1/8/2002
cwells : 1/3/2002
terry : 12/21/2001
carol : 11/9/2001
mcapotos : 11/7/2001
terry : 10/30/2001
mcapotos : 5/11/2001
terry : 5/7/2001
cwells : 5/4/2001
mcapotos : 5/2/2001
mcapotos : 4/27/2001
mcapotos : 4/26/2001
mcapotos : 4/3/2001
cwells : 2/20/2001
terry : 2/14/2001
cwells : 1/26/2001
terry : 1/24/2001
mcapotos : 9/5/2000
mcapotos : 8/31/2000
carol : 5/30/2000
alopez : 4/14/2000
terry : 4/14/2000
mcapotos : 2/14/2000
mcapotos : 2/8/2000
terry : 2/1/2000
carol : 1/31/2000
terry : 1/31/2000
mgross : 1/10/2000
terry : 12/15/1999
carol : 10/25/1999
carol : 10/13/1999
jlewis : 8/26/1999
terry : 8/5/1999
carol : 2/23/1999
terry : 2/20/1999
carol : 1/13/1999
terry : 1/7/1999
carol : 9/16/1998
terry : 9/11/1998
alopez : 8/31/1998
carol : 8/27/1998
terry : 8/26/1998
terry : 8/25/1998
terry : 8/21/1998
terry : 8/21/1998
terry : 8/21/1998
terry : 8/21/1998
alopez : 5/21/1998
psherman : 3/27/1998
psherman : 3/24/1998
dholmes : 3/4/1998
alopez : 1/15/1998
terry : 12/18/1997
terry : 11/11/1997
terry : 10/20/1997
terry : 9/12/1997
terry : 9/5/1997
terry : 7/11/1997
terry : 7/11/1997
terry : 6/24/1997
terry : 6/21/1997
mark : 9/25/1996
carol : 9/17/1996
terry : 8/19/1996
terry : 7/29/1996
mark : 3/4/1996
terry : 2/20/1996
mark : 1/17/1996
mark : 1/17/1996
mark : 10/15/1995
terry : 11/14/1994
carol : 9/12/1994
jason : 7/14/1994
carol : 10/18/1993
carol : 5/26/1993

* 590050

TRANSFER RNA, MITOCHONDRIAL, LEUCINE, 1; MTTL1


Alternative titles; symbols

tRNA-LEU, MITOCHONDRIAL, 1


HGNC Approved Gene Symbol: MT-TL1

SNOMEDCT: 18773000, 230426003, 237619009, 237950009, 25792000, 267718000, 39925003, 447292006, 51178009, 67434000, 77835008;   ICD10CM: E71.111, E88.41, E88.42, G43.A, H35.30, H49.81, R11.15;   ICD9CM: 362.50, 798.0;  



TEXT

The mitochondrial tRNA for leucine (UUR) is encoded by nucleotides 3230-3304. (In UUR, R = A or G.)


Gene Function

Transcription termination of the mitochondrial genome requires binding of mitochondrial transcription termination factor (MTERF; 602318) to a 13-bp termination sequence (mitochondrial DNA nucleotides 3237 to 3249) located within the tRNA-leu(UUR) gene. Using gel filtration and PCR for repeated selection of bound sequences from a random pool of double-stranded DNA, Nam and Kang (2005) found that MTERF bound a 16-bp consensus sequence containing the 13-bp termination sequence within tRNA-leu(UUR). MTERF bound single-stranded DNA containing this sequence from the mitochondrial light strand, but not the heavy strand. Nam and Kang (2005) hypothesized that preferential binding of MTERF to the light strand may explain its orientation-dependent termination activity.


Biochemical Features

Yakubovskaya et al. (2010) determined the 2.2-angstrom crystal structure of mature human MTERF1 bound to double-stranded DNA (nucleotides 3232 to 3253 of mitochondrial DNA) containing the termination sequence within leu-tRNA(UUR). They found that binding of MTERF1 to the termination sequence unwound the DNA molecule and promoted eversion of 3 nucleotides. Base flipping was critical for stable binding and transcriptional termination.


Molecular Genetics

The uridine in the wobble position of the anticodon of MTTL1 is modified to taurinomethyluridine. Yasukawa et al. (2000) found that MTTL1 containing the 3243A-G (590050.0001) or 3271T-C (590050.0002) mutations, both of which result in MELAS syndrome (540000), lack this modification. They hypothesized that the lack of this modification may lead to the mistranslation of leucine into noncognate phenylalanine codons by the mutant tRNA, according to the mitochondrial wobble rule, and/or a decrease in the rate of mitochondrial protein synthesis. Yasukawa et al. (2000) suggested that the lack of uridine modification may explain why 2 different mutations manifest indistinguishable clinical features.

By molecular surgery of wildtype MTTL1 purified from human placenta, Kirino et al. (2004) created MTTL1 in which the taurinomethyluridine was replaced by unmodified uridine in order to examine the wobble modification deficiency independent of the pathogenic 3243A-G and 3271T-C mutations. Using an in vitro mitochondrial translation system, they demonstrated that the lack of taurinomethyluridine in MTTL1 results in a codon-specific translational deficiency. The tRNA bearing the unmodified wobble uridine showed strong binding to the UUA codon, but only weak binding to the UUG codon. Kirino et al. (2004) concluded that the lack of taurinomethyluridine modification results in an inability of MTTL1 to form codon-anticodon basepairs with UUG, and that the modified wobble uridine plays a functional role in the decoding of UUG codons by stabilizing the U:G wobble basepairing on the ribosomal A site.

From human cytoplasmic hybrids (cybrids) containing 3243A-G tRNA-leu(UUR) mutant or wildtype mitochondria from heteroplasmic MELAS patient myoblasts, Li and Guan (2010) developed a nearly homoplastic mutant cybrid line and an isogenic homoplastic wildtype cybrid line. They found that overexpression of LARS2 (604544) in the mutant cybrid line, but not the wildtype cybrid line, increased the steady-state level of aminoacylated tRNA-leu(UUR) and the rate of RNA processing and translation and restored mitochondrial respiration.


ALLELIC VARIANTS 12 Selected Examples):

.0001   MELAS SYNDROME

DIABETES AND DEAFNESS, MATERNALLY INHERITED, INCLUDED
MUSCLE STIFFNESS, PAINFUL, INCLUDED
3-@METHYLGLUTACONIC ACIDURIA, INCLUDED
MACULOPATHY, AGE-RELATED, INCLUDED
CYCLIC VOMITING SYNDROME, INCLUDED
MITOCHONDRIAL COMPLEX IV DEFICIENCY, INCLUDED
MERRF/MELAS OVERLAP SYNDROME, INCLUDED
MTTL1, 3243A-G
SNP: rs199474657, ClinVar: RCV000010206, RCV000010208, RCV000010209, RCV000010210, RCV000010211, RCV000022901, RCV000022902, RCV000032997, RCV000143997, RCV000224855, RCV000495738, RCV000626561, RCV000763623, RCV001794441, RCV002250458, RCV002285005, RCV002287327, RCV003325938, RCV003984803

The 3243A-G MTTL1 mutation is the most common heteroplasmic mtDNA mutation associated with disease. The percentage of mutated mtDNA decreases in blood as patients get older (Pyle et al., 2007).

PHENOTYPES

Goto et al. (1990) and Kobayashi et al. (1990) independently reported an mtDNA point mutation associated with the MELAS syndrome (540000). Kobayashi et al. (1991) showed that the A-to-G transition at nucleotide 3243 in the tRNA-leu (UUR) gene was indeed the cause of MELAS. (In UUR, R = A or G.) They isolated, from the same muscle tissue of a patient with MELAS, cell lines with distinctly different phenotypes: one was respiration-deficient and the other was apparently normal. The respiration-deficient cells were found to carry the abnormality in mtDNA. The mutation was found in 8 patients from unrelated families who had the mutation in heteroplasmic form, but was not found in control persons. Enter et al. (1991) likewise found this mutation in heteroplasmic form in Caucasian patients with the MELAS syndrome. This point mutation lies within a DNA segment responsible for transcription termination of the rRNA genes.

By histochemical, immunohistochemical, and single-fiber polymerase chain reaction (PCR) analysis, Moraes et al. (1992) demonstrated that ragged-red fibers in MELAS syndrome were associated with high levels of mutant mitochondrial genomes and with partial cytochrome c oxidase deficiency.

Ciafaloni et al. (1992) found the nucleotide 3243 mutation in 21 of 23 patients with MELAS and in all 11 oligosymptomatic and 12 of 14 asymptomatic relatives, but in only 5 of 50 patients with mitochondrial disease without features of MELAS. The proportion of mutant genomes in muscle ranged from 56 to 95% and was significantly higher in the patients with MELAS than in their oligosymptomatic or asymptomatic relatives. In those in whom both muscle and blood were studied, the percentage of mutations was significantly lower in blood and was not detected in 3 of 12 asymptomatic relatives.

In 2 patients with classic features of MELAS, Lertrit et al. (1992) found the A-to-G base substitution at nucleotide 3243 of tRNA(leu) in one and an 11084A-G mutation of ND4 in the other (516003.0001). The patient with the 3243A-G mutation was a 29-year-old woman with a 2-year history of classic migraine, recurrent stroke-like episodes with bilateral occipital infarction, recurrent occipital seizures, electroencephalogram consistent with encephalopathy, and high lactate and pyruvate levels in blood and cerebrospinal fluid. Muscle biopsy demonstrated extensive ragged-red fibers. Mosewich et al. (1993) studied a large family with the 3243 mutation as the cause of the MELAS syndrome. Family members had various combinations of sensorineural hearing loss, retinal pigmentary degeneration, migraine, hypothalamic hypogonadism, and mild myopathy. Only one member had a stroke-like episode at the age of 46 years. This patient had the highest percentage of mitochondrial chromosomes carrying the point mutation.

Matthews et al. (1994) described a woman without neurologic symptoms who died suddenly at the age of 42 of cardiomyopathy and lactic acidosis. Heteroplasmy for the 3243 mutation was found with a higher proportion of mutant mtDNA in heart (0.49), skeletal muscle (0.56), and liver (0.55) than in other tissues studied, for example, kidney (0.03). Vilarinho et al. (1997) reported a 6-year-old Portuguese boy with dilated cardiomyopathy, lactic acidosis, and no evidence of neurologic abnormality. Molecular genetic analysis showed the 3243 mutation in 88% of total muscle mtDNA and in 68% of the blood mitochondrial genome. Lower percentages were detected in blood from the mother (43%) and brother (49%). The brother had asymptomatic mild hyperlactic acidemia.

In a family of Indonesian descent, de Vries et al. (1994) found that clinical severity of MELAS varied directly in proportion to the quantity of mutated mitochondrial DNA in different tissues. The eldest of 5 children suffered from increasing sensorineural hearing loss after 15 years of age. The third-born sib had severe convulsions at the age of 18 years with stroke-like episodes and lactic acidosis. The fifth-born sib had unusually severe manifestations of MELAS with first manifestations at 7 years of age and death at the age of 14 years from severe cardiomyopathy. The clinically unaffected mother had 35% mutated mtDNA in her muscle but no mutated mtDNA in blood or fibroblasts.

As discussed in 520000, the maternally inherited diabetes-deafness syndrome (MIDD) without the manifestations of MELAS syndrome has been observed in association with an A-to-G transition at nucleotide 3243 in the MTTL1 gene (van den Ouweland et al., 1992). Reardon et al. (1992) and Schulz et al. (1993) described kindreds in which members with the maternally transmitted diabetes-deafness syndrome had an A-to-G transition at nucleotide 3243 of MTTL1.

Manouvrier et al. (1995) observed the 3243A-G mutation in the MTTL1 gene segregating with maternally inherited diabetes mellitus, sensorineural deafness, hypertrophic cardiomyopathy, or renal failure in a large pedigree with 35 affected members in 4 generations. Presenting symptoms almost consistently involved deafness and recurrent attacks of migraine-like headaches, but the clinical course of the disease varied within and across generations. Hypertrophic cardiomyopathy had not previously been a common finding in persons with the 3243A-G mutation and renal failure had not been reported.

Odawara et al. (1995) found the 3243 mutation in 3 of 300 patients with noninsulin-dependent diabetes mellitus or impaired glucose tolerance, and in none of 94 insulin-dependent diabetes mellitus or 115 nondiabetic controls. None of the patients with the mutation had significant sensorineural hearing loss.

Yang et al. (1995) described a 32-year-old Taiwanese woman in whom MELAS syndrome associated with diabetes mellitus and hyperthyroidism was caused by an A-to-G transition at nucleotide 3243 in the MTTL1 gene. In blood cells, approximately 60% of mtDNA was of the mutant type. In Taiwan, Chuang et al. (1995) found the A-to-G mutation at position 3243 in the MTTL1 gene in 1 of 23 pedigrees with multiple sibs affected with NIDDM. The pedigree was consistent with mitochondrial disease in terms of maternal transmission, relatively early onset, nonobesity, insulin-requirement, and association with hearing impairment. There was no correlation between the degree of heteroplasmy of the mitochondrial gene mutations in leukocyte DNA and clinical severity. Thus, the A-to-G transition at nucleotide 3243 is associated with 2 clinically distinct maternally transmitted syndromes: MELAS and noninsulin-dependent diabetes mellitus (NIDDM) with sensorineural hearing loss. In some populations the latter syndrome of maternally-inherited diabetes and deafness may represent 1 to 3% of all cases of NIDDM (Velho et al., 1996).

Yorifuji et al. (1996) reported this mutation in a mother with diabetes mellitus and sensorineural hearing loss and in her son. The clinical picture in the boy included short stature (as a result of deficient growth hormone secretion), moderate mental retardation, progressive nephropathy, and diabetes mellitus. Estimated percentages of mutated mtDNA were 11.8% in the child and 5.1% in the mother. In the renal biopsy specimen from the child, the percentage of mutated mtDNA was 65.6%. Yorifuji et al. (1996) proposed that nephropathy in the child was a result of this mutation. They suggested that mitochondrial disease should be taken into account when a patient has nephropathy of unknown cause.

Morten et al. (1995) sequenced part of the mtDNA control region in 11 unrelated patients heteroplasmic for the 3243 mutation associated with the MELAS phenotype. Only 2 patients shared the same sequence haplotype, implying that the 3243 mutation occurs independently in the maternal lineages of most MELAS patients.

Damian et al. (1996) reported a family in which a female infant with VACTERL (the association of vertebral, anal, cardiovascular, tracheoesophageal, renal, and limb defects; 192350) died at age 1 month due to renal failure. Her mother and sister later developed classic mitochondrial cytopathy associated with the A-to-G point mutation at nucleotide 3243 of mtDNA. Molecular analysis of mtDNA in preserved kidney tissue from the infant with VACTERL demonstrated 100% mutant mtDNA in multicystic and 32% mutant mtDNA in normal kidney tissue. Mild deficiency of complex I respiratory chain enzyme activity was found in the mother's muscle biopsy. Other maternal relatives were healthy but had low levels of mutant mtDNA in blood. Damian et al. (1996) stated that this was the first report to provide a precise molecular basis for a case of VACTERL. Stone and Biesecker (1997) were studying a cohort of 62 patients with VACTERL association. All of the children had normal chromosomes; only 1 had symptoms suggestive of mitochondriopathy, i.e., deafness and muscle weakness. All children had at least 3 of the 6 categories of anomalies associated with VACTERL. None of the affected children had levels of the 3243 mutation that were detectable by the methods used. Stone and Biesecker (1997) recognized the limitations of their study such as heteroplasmy of different tissues (only lymphocytes were studied). Stone and Biesecker (1997) suggested that the proposita reported by Damian et al. (1996) may have had oculoauriculovertebral dysplasia (164210) rather than VACTERL association.

Feigenbaum et al. (1996) also described a family that expanded the extreme clinical variability known to be associated with the A-to-G transition at nucleotide position 3243 of MTTL1. The propositus, a fraternal twin, presented at birth with clinical manifestations consistent with diabetic embryopathy, including anal atresia, caudal dysgenesis, and multicystic dysplastic kidneys. His cotwin, also male, was normal at birth, but at 3 months of age presented with intractable seizures later associated with developmental delay. The twins' mother developed diabetes mellitus type I at the age of 20 years and gastrointestinal problems at 22 years. Since age 19 years, the maternal aunt had had recurrent strokes, seizures, mental deterioration, and deafness, later diagnosed as MELAS syndrome due to the A-to-G mutation. A maternal uncle had diabetes mellitus type I, deafness, and normal intellect, and died at 35 years of age after recurrent strokes. This pedigree raised the possibility that, in some cases, diabetic embryopathy may be due to a mitochondrial cytopathy that affects both the mother's pancreas (and results in diabetes mellitus and the metabolic dysfunction associated with it) and the embryonic/fetal and placental tissues which make the embryo more vulnerable to this insult.

Velho et al. (1996) detected the 3243 mutation in 25 of 50 tested members of 5 white French pedigrees. Mutation-positive family members presented variable clinical features, ranging from normal glucose tolerance to insulin-requiring diabetes. They described the clinical phenotypes of affected members and detailed evaluations of insulin secretion and insulin sensitivity in 7 mutation-positive individuals who had a range of glucose tolerance from normal to impaired to NIDDM. All subjects, including those with normal glucose tolerance, demonstrated abnormal insulin secretion on at least 1 test. The data suggested to Velho et al. (1996) that a defect of glucose-regulated insulin secretion is an early and possible primary abnormality in carriers of the mutation. They speculated that this defect may result from the progressive reduction of oxidative phosphorylation and may implicate the glucose-sensing mechanism of beta cells.

Tamagawa et al. (1997) described the audiologic features in patients with hearing loss associated with the 3243A-G mutation. Four patients without and 5 patients with MELAS were studied. Most of the patients had bilateral progressive sensorineural hearing loss. The most common shape of the audiogram was sloping, while cases in the advanced stages had flat audiograms. Speech discrimination scores were generally poor and did not parallel the degree of hearing loss. The studies suggested that the lesion for hearing loss could include both cochlear and retrocochlear involvement, but did not demonstrate a significant difference in the audiologic findings between patients with and those without MELAS.

Lam et al. (1997) reported the case of a boy in whom MELAS appeared to be precipitated by valproate therapy. He had mild mental retardation and a right-sided convulsion at the age of 12 years. About 1 year later he experienced a similar seizure and was then treated with sodium valproate (200 mg 3 times daily). Eight days after initiation of valproate, he developed right hemiparesis and hypotonia and had 2 seizures. The serum levels of valproate were not excessive, but when no improvement occurred an idiosyncratic drug reaction was suspected and valproate was discontinued. Blood lactate and pyruvate were found to be elevated. Brain CT scan showed a left parietooccipital infarct and bilateral basal ganglia calcification. Muscle biopsy showed ragged-red fibers. Electron microscopy of muscle showed increased numbers of mitochondria and atypical mitochondria in the subsarcolemmal region, some with inclusion bodies. A 3243A-G mutation was detected in mitochondrial DNA from this patient. This mutation predisposed the patient to the detrimental effects of valproate on oxidative phosphorylation. The findings of Lam et al. (1997) supported the suggestion that valproate should not be given to patients suspected of having mitochondrial diseases. In addition, for patients whose seizures worsen with valproate therapy, an inborn error of mitochondrial metabolism should be suspected.

In a 21-year-old male patient with overlapping MELAS and Kearns-Sayre syndrome, Wilichowski et al. (1998) demonstrated the 3243A-G mutation in the MTTL1 gene. Progressive external ophthalmoplegia, pigmentary retinopathy, and right bundle branch block were present when he experienced the first stroke-like episode at 18 years of age. The 3243A-G mutation was found in 79% of mitochondrial DNA and was present at low levels in fibroblasts (49%) and blood cells (37%). Biochemical analysis showed diminished activities of pyruvate dehydrogenase (23%) and respiratory chain complexes I and IV (57%) in muscle, but normal activities in fibroblasts. Immunochemical studies showed normal content of E1-alpha, E1-beta, and E2 proteins. No nuclear mutation of the E1-alpha gene (PDHA1; 300502) was found. These observations suggested that mitochondrial DNA defects may be associated with altered nuclear encoded enzymes that are actively imported into mitochondria and constitute components of the mitochondrial matrix.

Dashe and Boyer (1998) discussed the case of a 13-year-old girl with a relapsing-remitting neurologic disorder that proved to be MELAS. The 3243A-G mitochondrial mutation was identified. The patient had had a normal childhood, although she was awkward at running, bicycle riding, and gymnastics. Twenty-six months before admission, she had an acute febrile episode with otitis, pharyngitis, headache, drowsiness, imbalance, and confusion, and abnormalities of the cerebral cortex were found by MRI and computed tomography (CT). The following month the girl had a grand mal seizure, followed by cortical blindness for 18 hours, with slow resolution. Three sibs of the mother had died in childhood. One, an older brother, never walked and died at 2 years of age of 'Schilder's disease;' another brother died in infancy of a 'high fever;' and a sister died of 'malnutrition' at 4 years of age. Both the proband's mother and a maternal uncle had hearing loss. Disorders causing strokes or stroke-like episodes in children were reviewed, including disorders of blood vessels or blood and metabolic disorders. In this case, analysis of mitochondrial DNA in skeletal muscle and cerebellum showed that 88% of the mitochondrial DNA was mutant. Over a period of 7 or 8 years the patient continued to have seizures that were difficult to control, accompanied by decline in cognition, hearing, vision, and balance. By the age of 20 years, she could no longer walk. Endocrinopathies, including hypothyroidism, inappropriate release of antidiuretic hormone, and diabetes mellitus developed in her late teens. She died with sepsis and multiorgan failure at the age of 23 years.

Chinnery et al. (1998) demonstrated that for both the MELAS 3243A-G mutation and the MERRF 8344A-G mutation (590060.0001) higher levels of mutant mtDNA in the mothers' blood were associated with an increased frequency of affected offspring. They also found that at any one level of maternal mutation load there was a greater frequency of affected offspring for the MELAS 3243A-G mutation than for the MERRF 8344A-G mutation.

Sue et al. (1999) reported 3 unrelated children with the 3243A-G mutation who presented with severe psychomotor delay in early infancy. One patient's clinical picture was more consistent with Leigh syndrome, with apneic episodes, ataxia, and bilateral striatal lesions on brain MRI. A second patient had generalized seizures refractory to treatment and bilateral occipital lesions on brain MRI. The third child had atypical retinal pigmentary changes, seizures, areflexia, and cerebral atrophy on brain MRI. All patients had several atypical features in addition to early onset: absence of an acute or focal neurologic deficit, variable serum and cerebrospinal fluid lactate levels, and lack of ragged-red fibers in muscle biopsy specimens. The proportion of mutant mtDNA in available tissues was relatively low (range, 5 to 51% in muscle and 4 to 39% in blood). The observations extended the phenotypic expression of the 3243A-G 'MELAS' mutation, and confirmed previous observations that there is 'poor correlation between abundance of mutant mtDNA in peripheral tissues and neurologic phenotype.'

Deschauer et al. (1999) detected the 3243A-G mutation heteroplasmatically in DNA from muscle and blood of a 61-year-old patient who at the age of 54 developed a myopathy with painful muscle stiffness as the predominant symptom. Additionally, a hearing impairment requiring a hearing aid for the left ear, numbness of the left arm and leg, and impaired glucose tolerance were present. Nocturnal sleep was severely disturbed by the pain. Neurologic examination showed generalized induration of muscles of the trunk and the upper and lower limbs at rest. Palpation of muscles was painful. On passive motion, there was a contracture-like resistance. A stiff-legged gait was observed, caused by pain and contracture. Muscle histopathology showed a few ragged-red fibers.

Smith et al. (1999) studied 13 subjects with the 3243A-G mutation from 7 different pedigrees with maternally inherited diabetes and deafness to evaluate the association of retinal disease. Visual symptoms, particularly loss of visual acuity, appeared to be infrequent. Test findings suggested that the retinal dystrophy involved defective functioning of retinal pigment epithelial cells and of both rod and cone photoreceptors. The pigmentary retinopathy did not prevent diabetic retinopathy; one subject had evidence of both disorders. The authors stated that the 3243A-G mutation accounts for 0.5 to 2.8% of diabetes.

Latkany et al. (1999) reported the ocular findings in 4 family members with MELAS syndrome caused by the 3243A-G transition in the MTTL1 gene. Findings included ophthalmoplegia, neurosensory deafness, reduced photopic and scotopic electroretinogram (ERG) b-wave amplitudes, myopathy, and slowly progressive geographic macular retinal pigment epithelium atrophy.

Aggarwal et al. (2001) found the same mutation in a 29-year-old woman with gestational diabetes, deafness, Wolff-Parkinson-White (WPW) syndrome (194200), placenta accreta, and premature graying. Premature graying of the hair had started at age 15 years. Placenta accreta is a rare disorder, occurring especially in primigravidae. The features are 'retained placenta' and severe postpartum hemorrhage. The authors claimed this to be the first report of an association of the 3243A-G mtDNA mutation with WPW syndrome; a study of 27 other patients with WPW syndrome failed to reveal this mutation. The patient's sister also suffered from WPW syndrome, premature graying, and sensorineural deafness.

De Kremer et al. (2001) described a child with a 3243A-G mutation of mtDNA in all tissues. The patient had severe failure to thrive, severely delayed gross motor milestones, marked muscle weakness, and dilated cardiomyopathy. He also developed neutropenia at age 4 years. Laboratory studies showed persistently elevated urinary levels of 3-methylglutaconic and 2-ethylhydracrylic acids and low blood levels of cholesterol. The child died at age 4.5 years. De Kremer et al. (2001) suggested that Barth-like syndrome should be added to the list of phenotypes observed with the MELAS mutation.

In Finland, Uimonen et al. (2001) estimated the rate of progression of deafness in patients with the 3243A-G mutation. They examined 14 men and 24 women. The impairment of hearing was worse in men than in women, and women outnumbered men among patients with normal hearing or mild hearing impairment. The rate of progression was calculated to be 2.9 dB per year in men and 1.5 dB per year in women. A high degree of mutant heteroplasmy, male gender, and age were found to increase the severity of hearing impairment.

Deschauer et al. (2001) found the 3243A-G mutation in 16 patients with mitochondrial encephalomyopathies (10 index patients and 6 symptomatic relatives). Only 6 of these patients presented with stroke-like episodes and met the classic criteria of MELAS syndrome. One had MELAS/MERRF overlap syndrome. Two patients presented with stroke-like episodes but did not meet the classic criteria of MELAS. Of the 8 other patients, 1 had myopathy with hearing loss and diabetes mellitus, 1 had chronic progressive external ophthalmoplegia, 1 had diabetes mellitus with hearing loss, 1 had painful muscle stiffness with hearing loss, 1 had cardiomyopathy, 1 had diabetes mellitus, and 2 had hearing loss as predominant features. In 11 of the 16 patients, hearing impairment was obvious on clinical examination. Furthermore, all 5 patients with normal hearing on clinical examination showed subclinical hearing loss.

Chinnery et al. (2001) studied 9 patients from 4 families with the 3243A-G mutation; only 1 of the patients demonstrated severe neurologic disease with a proximal myopathy. Detailed study of resting and active muscle phosphate, creatine, and ATP synthesis failed to show any relationship between mutation load (percentage of mutated mtDNA in the muscle) and mitochondrial function in vivo. The authors suggested that nuclear genetic factors may play a modifying role in mitochondrial dysfunction.

Petruzzella et al. (2004) described cerebellar ataxia as an atypical manifestation of the 3243A-G MELAS mutation. The patient was a 55-year-old man who denied a family history of neurologic diseases and presented a 10-year history of progressive speech and balance disturbances. IQ was not affected. There was mild proximal muscle weakness and hypotrophy in the upper limb girdle muscles. The concurrence of muscle weakness and atrophy raised the suspicion of mitochondrial involvement, prompting testing. The 3243A-G mutation was found in relatively low abundance.

Jones et al. (2004) tested 570 patients with early or late age-related maculopathy (see 603075) for the 3243A-G mutation in mtDNA. Only 1 study participant with early ARM, hypertension, ischemic heart disease, and asthma was found to carry the 3243A-G mutation. Jones et al. (2004) concluded that the 3243A-G mutation is a very rare cause of typical ARM in the general population.

Salpietro et al. (2003) identified the 3243A-G mutation in 4 affected members of an Italian family with cyclic vomiting syndrome (500007). The youngest affected member, a 5-year-old boy, had 70% mutant mtDNA in peripheral blood. The boy's mother, maternal aunt, and maternal grandmother, who were all affected, had 35%, 30%, and 25% mutant mtDNA, respectively. There was a positive correlation between amount of mutant mtDNA and clinical severity. The 3 adults were affected by the syndrome during childhood and developed migraine headaches as adults.

Bohm et al. (2006) identified the 3243A-G mutation in 6 unrelated patients with mitochondrial complex IV deficiency (220110).

Donovan and Severin (2006) reported a kindred in which 4 of 7 sibs had adult-onset diabetes mellitus and sensorineural hearing loss with a confirmed mutation at position 3243 in the tRNA. Two other sibs in this kindred demonstrated different phenotypes of mitochondrial disease. After 1 year of treatment with coenzyme Q10, repeat stress thallium testing demonstrated improvement in the exercise tolerance of the proband from 7 to 12 minutes. Audiometry testing did not demonstrate a change in the rate of hearing decline.

In a study of 51 Danish individuals with the 3243A-G mutation, Jeppesen et al. (2006) found that skeletal muscle mutation load correlated inversely with maximal oxygen update and maximal workload during cycling exercise. Resting venous lactate directly corresponded to muscle mutation load. Those with COX-negative and/or ragged red fibers had over 50% mutation load in muscle, and all those with hearing impairment and diabetes mellitus or hearing impairment alone had more than 65% mutation load. In contrast, mutation load in blood was not correlated, or only weakly correlated, with these parameters. Jeppesen et al. (2006) concluded that the threshold at which oxidative impairment and muscle symptoms occur is as low as 50 to 65% in patients with the 3243A-G mutation, a level that is lower than previously reported based on cell culture studies.

Janssen et al. (2008) defined the 'mitochondrial energy-generating system' (MEGS) capacity as a measurement encompassing mitochondrial enzymatic reactions from oxidation of pyruvate to the export of ATP, which can be used as an indicator for overall mitochondrial function. In an analysis of muscle tissue from 24 MELAS patients with the 3243A-G mutation, MEGS capacity correlated better with mutation load than did analysis of individual respiratory chain enzyme activities, including complex I, III, and IV. The sensitivity and specificity of measurement using MEGS reached 78% and 100%, respectively, for a mitochondriopathy, which was significantly more accurate than measuring individual enzyme activities alone.

In a review of 45 probands with the 3243A-G mutation, Kaufmann et al. (2009) found variable involvement of multiple organ systems. In addition to classic MELAS features, patients had psychiatric problems, hearing loss, diabetes, exercise intolerance, gastrointestinal disorders, short stature, and learning disabilities.

In a patient with MELAS due to the 3243A-G mutation, Costello and Sims (2009) reported safe and effective treatment of symptomatic myoclonus with lamotrigine.

Nakamura et al. (2010) reported a family in which 4 members carried both the 3243A-G mutation and a 8356T-C transition in the MTTK gene (590060.0002), which is usually associated with MERFF syndrome. The female proband and her cousin had MERFF, a deceased aunt had a MERFF/MELAS overlap syndrome, and the mother of the proband was asymptomatic. Genetic analysis showed that the double mutations were heteroplasmic in blood of the proband and her cousin but at low levels in her asymptomatic mother. In muscle tissue of the proband and her aunt, the proportion of the 3243A-G mutation was higher than in blood, and the 8356T-C mutation was homoplasmic. Nakamura et al. (2010) hypothesized that the phenotype in affected individuals began with MERFF and evolved into MELAS later in life.

In a questionnaire-based survey, Parsons et al. (2010) found that 28 (80%) of 35 patients with MELAS due to the 3243A-G mutation and 33 (62%) of 53 carrier relatives reported autonomic symptoms compared to 2 (12%) of 16 controls. Gastrointestinal symptoms, orthostatic dizziness, and cold or discolored hands and feet were the most common complaints among mutation carriers.

In a retrospective study, Malfatti et al. (2013) found that 38 of 41 individuals with the MTTL1 c.3243A-G mutation had symptoms consistent with MELAS, whereas 3 were asymptomatic. Cardiac investigations identified left ventricular hypertrophy and/or left ventricular dysfunction in 18 patients, along with Wolff-Parkinson-White syndrome in 7, conduction system disease in 4, and atrial fibrillation in 1. Over a median 5-year follow-up period, 11 patients died, including 3 due to heart failure. Malfatti et al. (2013) concluded that, after central neurologic disease, cardiac disease has the greatest impact on prognosis in patients with the c.3243A-G mutation. Left ventricular hypertrophy was the only independent prognostic risk factor for adverse cardiac events, suggesting that these patients should be closely monitored. The severity of cardiac disease and adverse events did not correlate with mutation load in blood or urine or with ragged-red fibers on muscle biopsy.

STUDIES OF THE 3243A-G MUTATION

Yoneda et al. (1992) studied the growth characteristics of cells carrying the MELAS mitochondrial mutation by introducing patient mitochondria into human mtDNA-less cells. Five of 13 clonal cell lines containing mixtures of wildtype and mutant mtDNAs were found to undergo a rapid shift of their genotype toward the pure mutant type. On the other hand, the other 8 cell lines, which included 6 exhibiting nearly homoplasmic mutant mtDNA, maintained a stable genotype. Subcloning experiments and growth rate measurements clearly indicated that an intracellular replicative advantage of mutant mtDNA was mainly responsible for the dramatic shift toward the mutant genotype observed in the unstable cell lines.

Matthews et al. (1995) showed that fibroblast clones from subjects heteroplasmic for the MELAS 3243A-G mutation show wide variability in the degree of heteroplasmy. The distribution of mutant mtDNA between different cells was not random about the mean, suggesting that selection against cells with high proportions of mutant mtDNA had occurred. To explore the way in which heteroplasmic mtDNA segregates in mitosis, they followed the distribution of heteroplasmy between clones over approximately 15 generations. There was either no change or a decrease in the variance of intercellular heteroplasmy for the MELAS 3243A-G mutation, which was considered most consistent with segregation of heteroplasmic units of multiple mtDNA molecules in mitosis. After mitochondria from one of the MELAS 3243A-G fibroblast cultures were transferred to a mitochondrial DNA-free cell line derived from osteosarcoma cells by cytoplast fusion, the mean level and intercellular distribution of heteroplasmy was unchanged. Matthews et al. (1995) interpreted the findings as evidence that somatic segregation (rather than nuclear background or cell differentiation state) is the primary determinant of the level of heteroplasmy.

Janssen et al. (1999) showed that cells harboring patient-derived mitochondria with an A-to-G transition at nucleotide position 3243 display severe loss of respiration. Despite the low level of leucyl-tRNA-Leu(UUR), the rate of mitochondrial translation was not seriously affected by this mutation. Therefore, a decrease of mitochondrial protein synthesis as such did not appear to be a necessary prerequisite for loss of respiration. Rather, the mitochondrially encoded proteins seemed subject to elevated degradation, leading to a severe reduction in their steady state levels. The results were interpreted as favoring a scheme in which the 3243 mutation causes loss of respiration through accelerated protein degradation, leading to a disequilibrium between the levels of mitochondrial and nuclear encoded respiratory chain subunits and thereby a reduction of functional respiratory chain complexes.

Borner et al. (2000) used an assay that combined tRNA oxidation and circularization to determine the relative amounts and states of aminoacylation of mutant and wildtype tRNAs in tissue samples from MELAS and MERRF (545000) patients. In most, but not all, biopsies from MELAS patients carrying the 3243A-G substitution, the mutant tRNA was underrepresented among processed and/or aminoacylated tRNAs. In contrast, in biopsies from MERRF patients harboring the 8344A-G substitution in the tRNA-lys gene (590060) neither the relative abundance nor the aminoacylation of the mutated tRNA was affected. The authors concluded that whereas the 3243A-G mutation may contribute to the pathogenesis of MELAS by reducing the amount of aminoacylated tRNA-leu, the 8344A-G mutation does not affect tRNA-lys function in MERRF patients in the same way.

Chomyn et al. (2000) presented several lines of evidence indicating that the protein synthesis defect in 3243A-G MELAS mutation-carrying cells is mainly due to a reduced association of mRNA with ribosomes, possibly as a consequence of the tRNA-leu(UUR) aminoacylation defect.

In a longitudinal study, Olsson et al. (2001) determined the proportion of the mitochondrial 3243A-G mutation in DNA obtained from cervical smear samples collected from 3 patients with maternally inherited diabetes and deafness. The proportion of mtDNA with the 3243A-G mutation decreased over time in the samples from all 3 patients: in patient 1 the mutant mtDNA decreased from 32 to 10% in 18 years, in patient 2 from 11 to 5% in 8 years, and in patient 3 from 26 to 19% in 4 years. This corresponded to a relative annual decline of 5.8% of the initial heteroplasmy level. The authors suggested that the observed decrease in mutational load with time was probably the consequence of negative selection acting against high levels of mutation load either at the level of cells or mitochondria due to impairment of the oxidative phosphorylation. The results may explain the observation of molecular genetic anticipation seen in some pedigrees with mitochondrial disorders. The percentage level of mutant mtDNA may be higher in the recent generation compared to the preceding one simply because the samplings were made on individuals of different ages in the pedigree.

The amount of 3243A-G heteroplasmy in blood tends to slowly decrease over time. Rahman et al. (2001) compared the levels of 3243A-G mutant mtDNA in blood at birth from Guthrie cards and at the time of diagnosis in a blood DNA sample from patients with MELAS syndrome. Paired blood DNA samples separated by 9 to 19 years were obtained from 6 patients. Quantification of mutant load demonstrated a decline (range 12 to 29%) in the proportion of mutant mtDNA in all cases. These results suggested that mutant mtDNA is slowly selected from rapidly dividing blood cells in MELAS. The authors showed that in elderly patients false-negative results may be obtained in testing for mitochondrial diseases when DNA from leukocytes is used. They proposed muscle and hair follicles as a better source of DNA.

Nam and Kang (2005) found that the 3243A-G mutation reduced, but did not eliminate, binding of recombinant human MTERF to the tRNA-leu(UUR) termination sequence.

Pyle et al. (2007) established an accurate fluorescent assay for 3243A-G heteroplasmy and the amount of mtDNA in blood with real-time PCR. The amount of mutated and wildtype mtDNA was measured at 2 time points in 11 subjects. The percentage of mutated mtDNA decreased exponentially during life, and peripheral blood leukocytes in patients harboring 3243A-G were profoundly depleted of mtDNA. A similar decrease in mtDNA had been seen in other mitochondrial disorders, and in 3243A-G cell lines in culture, indicating that depletion of mtDNA may be a common secondary phenomenon in several mitochondrial diseases. Thus, depletion of mtDNA is not always due to mutation of a nuclear gene involved in mtDNA maintenance.

Durham et al. (2007) showed that segments of human skeletal muscle fibers harboring 2 pathogenic mtDNA mutations retain normal cytochrome c oxidase (COX) activity by maintaining a minimum amount of wildtype mtDNA. For these mutations, direct measurements of mutated and wildtype mtDNA molecules within the same skeletal muscle fiber are consistent with the 'maintenance of wildtype' hypothesis, which predicts that there is nonselective proliferation of mutated and wildtype mtDNA in response to the molecular defect. However, for the 3243A-G mutation, a superabundance of wildtype mtDNA was found in many muscle fiber sections with negligible COX activity, indicating that the pathogenic mechanism for this particular mutation involves interference with the function of the wildtype mtDNA or wildtype gene products.

Using an anti-complex IV immunocapture technique and mass spectrometry, Janssen et al. (2007) found that COX I and COX II existed exclusively with the correct amino acid sequences in 3243A-G cells. The findings excluded a dominant-negative effect of the 3243A-G mutation, leaving tissue-specific accumulation by mtDNA segregation as the most likely cause of variable mitochondrial disease expression in patients with this mutation.

Rajasimha et al. (2008) observed an exponential decrease of mutant 3243A-G mtDNA in blood over time by simulating the segregation of the mutation in hematopoietic stem cells and leukocyte precursors. The findings were consistent with a selective process acting at the stem cell level and could explain why the level of mutant mtDNA in blood is almost always lower than that observed in nondividing tissues such as skeletal muscle. From human data (Rahman et al., 2001; Pyle et al., 2007), Rajasimha et al. (2008) derived a formula to correct for the change in heteroplasmy over time. The findings indicated that there is selection against pathogenic mtDNA in stem cells but not in committed blood cell precursors. The mechanism of loss of stem cells with high mutation levels was sufficient to explain the data, but other mechanisms may also be involved.

Sasarman et al. (2008) analyzed myoblasts isolated from a MELAS patient who was homoplasmic for the 3243A-G mutation. MELAS myoblasts showed only moderately affected translation of mitochondrial proteins, but an almost complete lack of assembly of respiratory chain complexes I, IV, and V. Pulse-chase labeling showed reduced stability of all mitochondrial translation products consistent with an assembly defect. There was also evidence of amino acid misincorporation in 3 polypeptides: MTCO3 (516050), MTCO2 (516040), and ATP6 (516060). The assembly defect could be partially rescued by overexpression of mitochondrial translation elongation factors EFTu (TUFM; 602389) or EFG2 (GFM2; 606544). The data indicated that the 3243A-G mutation produces both loss- and gain-of-function phenotypes, explaining the apparent discrepancy between the severity of the translation and respiratory chain assembly defects.

Yakubovskaya et al. (2010) identified 3243A as 1 of 3 nucleotides in leu-tRNA(UUR) that was everted during MTERF1 binding. The 3243A-G mutation reduced the affinity of MTERF1 binding to leu-tRNA(UUR).

Dvorakova et al. (2016) reported the comprehensive clinical phenotype of 50 Czech patients with the m.3243A-G mutation. Symptoms developed in 33 patients (66%) and 17 carriers remained unaffected (34%). The age of onset varied from 1 month to 47 years of age, with juvenile presentation occurring in 53% of patients. Myopathy was the most common presenting symptom (18%), followed by CPEO/ptosis and hearing loss, with the latter also being the most common second symptom. Stroke-like episodes occurred in 14 patients, although never as a first symptom, and were frequently preceded by migraines (58%). Rhabdomyolysis developed in 2 patients. The second symptom appeared 5.0 +/- 8.3 years (range 0-28 years) after the first, and the interval between the second and third symptom was 2.0 +/- 6.0 years (range 0-21 years). Four patients remained monosymptomatic up to 12 years of follow-up. The sequence of symptoms according to their time of manifestation was migraines, myopathy, seizures, CPEO/ptosis, stroke-like episodes, hearing loss, and diabetes mellitus. The average age at death was 32.4 +/- 17.7 years (range 9-60 years) in the juvenile form and 44.0 +/- 12.7 years (range 35-53 years) in the adult form. Some patients with stroke-like episodes harbored very low heteroplasmy levels in various tissues. No threshold for any organ dysfunction could be determined based on these levels.

POPULATION GENETICS

In an adult population of 245,201 individuals, Majamaa et al. (1998) studied the frequency of the 3243A-G mutation. In addition, they ascertained 615 patients with diabetes mellitus, sensorineural hearing impairment, epilepsy, occipital brain infarct, ophthalmoplegia, cerebral white matter disease, basal ganglia calcifications, hypertrophic cardiomyopathy, or ataxia, and examined 480 samples for the mutation. The mutation was found in 11 pedigrees, and its frequency was calculated to be 16.3/100,000 in the adult population. As determined by mtDNA haplotyping, the mutation had arisen in the population at least 9 times. Clinical evaluation of the probands revealed a syndrome that most frequently consisted of hearing impairment, cognitive decline, and short stature. The high prevalence of the common MELAS mutation in the adult population suggested that mitochondrial disorders constitute one of the largest diagnostic categories of neurogenetic diseases.

The low frequency of deleterious point mutations in mtDNA in human populations has suggested that they are under strong negative selection, and a reduced genetic fitness of mutation carriers had been assumed (Zeviani et al., 1998). In a population-based study of the 3243A-G mutation in the province of Oulu, Finland (Majamaa et al., 1998), Moilanen and Majamaa (2001) calculated the net reproduction rate for 31 mutation carriers and found it to be similar to that of the general population. The average fertility of mutation carriers was not reduced, and the generation time was not different between the mutation carriers and the general population. Moilanen and Majamaa (2001) stated that morbidity and mortality from the mutation may have changed compared to that of historical populations (e.g., diabetes mellitus may have proved fatal in earlier times but is now treatable). Moilanen and Majamaa (2001) concluded that the low frequency of this mutation in populations may still be explained by a mild uniform selection or a selection that depends on the degree of the mutant mtDNA heteroplasmy; alternatively, there may be no host-level selection at all, implying that other factors are responsible for the low population frequency.

Among 230 patients with sensorineural hearing loss in otorhinolaryngology clinics in Japan, Nagata et al. (2001) found 4 instances of the 3243A-G mutation (1.74%). Association of maternally inherited diabetes mellitus, cardiomyopathy, a family history of possible maternal inheritance of sensorineural hearing loss, and an onset of sensorineural hearing loss between the teenage years and the forties were signs suggesting the mutation.

Using high-resolution restriction fragment length polymorphism analysis and control-region sequencing, Torroni et al. (2003) studied 35 mtDNAs from Spain that harbored the 3243A-G mutation in association with either MELAS or a wide array of disease phenotypes. A total of 34 different haplotypes were found, indicating that all instances of the 3243A-G mutation are probably due to independent mutational events. Haplotypes were distributed into 13 haplogroups whose frequencies were close to those of the general Spanish population. Moreover, there was no statistically significant difference in haplogroup distribution between patients with MELAS and those with disease phenotypes other than MELAS. Torroni et al. (2003) concluded that the 3243A-G mutation may harbor all the evolutionary features expected from a severely deleterious mtDNA mutation under strong negative selection, and they reveal that European mtDNA backgrounds do not play a substantial role in modulating the mutation's phenotypic expression.

Uusimaa et al. (2007) estimated the prevalence of the 3243A-G mutation in northern Finland to be 18.4 in 100,000 children. The most common clinical manifestations appearing in childhood were sensorineural hearing loss, short stature or delayed maturation, migraine, learning difficulties, and exercise intolerance. Segregation analyses did not show a correlation between mother and child heteroplasmy, arguing against the random drift hypothesis.

Elliott et al. (2008) determined the frequency of 10 mitochondrial point mutations in 3,168 neonatal cord blood samples from sequential live births in North Cumbria in England, analyzing matched maternal blood samples to estimate the de novo mutation rate. Mitochondrial DNA mutations were detected in 15 offspring (0.54%, 95% confidence interval = 0.30-0.89%). Of these live births, 0.00107% (95% confidence interval = 0.00087-0.0127) harbored a mutation not detected in the mother's blood, providing an estimate of the de novo mutation rate. The most common mutation was mitochondrial 3243A-G. Elliott et al. (2008) concluded that at least 1 in 200 healthy humans harbors a pathogenic mitochondrial DNA mutation that potentially causes disease in the offspring of female carriers.


.0002   MELAS SYNDROME

MTTL1, 3271T-C
SNP: rs199474658, ClinVar: RCV000010212, RCV000507161, RCV000763624, RCV003319163

In 3 of 40 MELAS (540000) patients, Goto et al. (1991) found a T-to-C transition at nucleotide position 3271 in the mitochondrial tRNA-leu (UUR) gene. The change was very near the site of the most common mutation at 3243 (590050.0001). Hayashi et al. (1993) introduced mitochondrial DNA with the T3271C mutation into HeLa cells lacking mtDNA and showed that accumulation of more than 87% of the mutant form in the cybrid clones induced both low complex I activity and abnormal mtDNA-encoded polypeptide synthesis that included at least subunit ND6 of complex I.

Stenqvist et al. (2005) identified a heteroplasmic 3271T-C mutation in a patient with MELAS who died at age 18 years. The mutation was present in 90% of fibroblasts and 94% skeletal muscle. Stenqvist et al. (2005) stated that 7 to 15% of MELAS patients have the 3271T-C mutation.


.0003   MERRF SYNDROME

DIABETES MELLITUS, NONINSULIN-DEPENDENT, MATERNALLY TRANSMITTED
MTTL1, 3256C-T
SNP: rs199474659, ClinVar: RCV000010213, RCV000010214, RCV000850697, RCV003153298

In a patient with a neurologic syndrome resembling MERRF (myoclonus epilepsy and ragged-red fibers) plus optic neuropathy, retinopathy, and diabetes, Moraes et al. (1993) found a C-to-T transition at position 3256 within the mitochondrial tRNA-leu (UUR) gene. The patient was heteroplasmic for this mutation, with higher percentages of mutant mtDNA in affected tissues, and undetectable levels in maternal relatives. Analysis of single muscle fibers indicated that morphologic and biochemical alterations appeared only when the proportion of mutant mtDNA exceeded 90% of the total cellular mtDNA pool. Moraes et al. (1993) indicated that this was the ninth known mutation in the tRNA-leu (UUR) gene and suggested that this region is an 'etiologic hotspot' (not necessarily a mutation hotspot) in mitochondrial disease.

Hirai et al. (1998) studied a mitochondrial DNA mutation in a 45-year-old Japanese woman with noninsulin-dependent diabetes mellitus and muscle atrophy. They identified a mitochondrial DNA C-to-T heteroplasmic mutation at nucleotide position 3256. The mutation was located in a conserved region of the MTTL1 gene. Eight other members of her family were examined for the mutation. Six of them had the same mutation together with noninsulin-dependent diabetes mellitus, and 1 teenaged boy had the mutation and impaired glucose tolerance. The other family member who did not have the mutation had normal glucose tolerance. The enzyme activity of the mitochondrial oxidative phosphorylation pathway in the muscle of the proband was decreased, especially in complex I. The authors concluded that the mutation may be responsible for the abnormal glucose metabolism. No mention of deafness was made.


.0004   CARDIOMYOPATHY WITH OR WITHOUT SKELETAL MYOPATHY

MTTL1, 3303C-T
SNP: rs199474660, ClinVar: RCV000010215, RCV000850713, RCV003162234

Silvestri et al. (1994) described a C-to-T transition at nucleotide 3303 of mtDNA in 7 members of a family with cardiomyopathy and myopathy. The proband and 2 sibs had fatal infantile cardiomyopathy, whereas in 3 maternal relatives the disease manifested later in life as sudden cardiac death or as mitochondrial myopathy with cardiomyopathy. The mutation was homoplasmic in all tissues (including blood) from the proband and her brother, but heteroplasmic in blood from 5 oligosymptomatic or asymptomatic maternal relatives. The mutation disrupted a conserved basepair in the aminoacyl stem of the tRNA-leu (UUR).

The causative role of the 3303C-T mutation in the MTTL1 gene was confirmed by Bruno et al. (1999), who found the mutation in 8 patients from 4 unrelated families. In the first family, the clinical presentation was infantile cardiomyopathy; in the second family, proximal limb and neck weakness dominated the clinical picture for the first 10 years of life, when cardiac dysfunction became apparent; in the third family, 2 individuals presented with isolated skeletal myopathy and 2 others with skeletal myopathy and cardiomyopathy; in the fourth family, 1 patient had fatal infantile cardiomyopathy and the other had a combination of skeletal myopathy and cardiomyopathy.


.0005   ENCEPHALOMYOPATHY, MITOCHONDRIAL

MTTL1, 3252A-G
SNP: rs199474661, ClinVar: RCV000010217, RCV000850692

In a patient with mitochondrial encephalomyopathy, pigmentary retinopathy, dementia, hypoparathyroidism, and diabetes mellitus, Morten et al. (1993) found heteroplasmy in blood (30%) and muscle (76%) for a mutation at nucleotide 3252 in the MTTL1 gene. In the proband, mental retardation was first noted at the age of 4 years. She came to medical attention at the age of 11 with recurrent vomiting attributed to hiatus hernia. Mitochondrial encephalomyopathy was diagnosed at the age of 13 when she presented with frequent falls and increasing weakness. Muscle biopsy demonstrated 3% ragged red fibers, rising to 5 to 10% 7 years later. She went on to develop diabetes mellitus in her mid-teens, and cerebral atrophy was demonstrated by CT scan. By the age of 31, she had also developed hypoparathyroidism, worsening dementia, and pigmentary retinopathy, and her spastic paraparesis had progressed. She died of complete heart block, aspiration pneumonia, and renal failure at the age of 31 years. The mother, who had the mutation in 50% of muscle cells, developed progressive generalized weakness with spastic paraparesis and dysarthria when she was 44 years old. Muscle biopsy demonstrated 10% ragged red fibers. She died at the age of 58 years following a stroke-like episode. The maternal grandmother had difficulty walking and frequent falls from age 60 which was attributed to cerebellar degeneration. A sister of the proposita died suddenly of 'myocarditis' at the age of 7. Although she had no known neurologic or developmental impairment, there had been a longstanding renal problem. The A-to-G transition at nucleotide 3252 was located at a highly conserved position in the tRNA molecule, close to the 3243 mutation which is associated with more than 80% of MELAS cases.


.0006   PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, PROXIMAL MYOPATHY, AND SUDDEN DEATH

MTTL1, 3251A-G
SNP: rs199474662, ClinVar: RCV000010218, RCV000850691

Sweeney et al. (1993) reported a family exhibiting maternal inheritance of a variable syndrome comprising ocular, neck, and proximal upper limb weakness, psychiatric features, and sudden death. Of 15 definitely or probably affected individuals, 7 had died in early adult life, probably of respiratory failure. All living affected members of the family showed an A-to-G transition at nucleotide 3251 of the MTTL1 gene.

In a girl who died at age 14 from a rapidly progressive mitochondrial myopathy, Houshmand et al. (1996) found heteroplasmy for the A3251G mutation. A large proportion of muscle fibers contained accumulations of abnormal mitochondria but no cytochrome c oxidase deficient fibers were present. Studies of isolated muscle mitochondria revealed a profound isolated complex I deficiency. A high percentage of mutant mtDNA was found in muscle (94%), fibroblasts (93%), brain (90%), liver (80%), and heart (79%). The family was not available for investigation. The proportion of mutant mtDNA was 28% in normal-appearing fibers and 61% in abnormal fibers. The patient had been healthy until age 10 years when she had insidious onset of gastrointestinal symptoms with diarrhea, nausea, fatigue, and tachycardia on mild physical exertion. Terminally, in the last years of life she developed persistent tachycardia, lactic acidosis, and hypercapnia, and in the last month of life, cardiorespiratory failure.


.0007   CARDIOMYOPATHY WITH OR WITHOUT SKELETAL MYOPATHY

MTTL1, 3260A-G
SNP: rs199474663, ClinVar: RCV000010219, RCV000850698

Mariotti et al. (1994) studied a 23-year-old man, subject III-1 in the report by Zeviani et al. (1991), who suffered from heart failure and muscle weakness due to skeletal myopathy with ragged-red fibers. He had signs of congestive heart failure. Densitometric quantitation showed that 90% of mtDNA extracted from skeletal muscle was mutant. A point mutation in the MTTL1 gene was shown to be an A-to-G transition at nucleotide position 3260. The disorder was of adult onset and inherited from the mother. From study of respiratory capacity and mitochondrial protein synthesis in transformant cybrids harboring the mutation, Mariotti et al. (1994) proved that the G3260 mutation was responsible for the clinical disorder in this family. They recommended the transformant cybrid system for evaluating the pathogenic potential of mtDNA mutations.


.0008   SKELETAL MYOPATHY, RESPONSIVE TO RIBOFLAVIN

MTTL1, 3250T-C
SNP: rs199474664, ClinVar: RCV000010216, RCV000850690

Ogle et al. (1997) reported the case of a young girl with complex I deficiency and skeletal myopathy who had a sustained clinical response to riboflavin during 3 years of therapy. She had been noted from the age of 13 months to hold her head in the flexed position when walking. At 2 years of age, she required assistance with standing from the seated position, frequently complained of tiredness after walking short distances, and often stumbled. There was severe weakness of neck extensors, but she could extend her head against gravity. There was marked lumbar lordosis, mild proximal weakness, a mild decrease in tone peripherally, and normal deep tendon reflexes. Muscle bulk was normal. There was no ptosis, ophthalmoplegia, or hepatosplenomegaly. Molecular studies found no mutations in the putative flavin mononucleotide binding site in the 51-kD subunit of complex I, but a T-to-C transition at nucleotide 3250 was identified in the MTTL1 gene. The mutation was present in a heteroplasmic state. The same mutation had been reported by Goto et al. (1992) in a family with 5 members who had fatigue with or without muscle weakness. There were also 5 sibs in this family who had died in early childhood of unknown causes. In the family reported by Ogle et al. (1997), 2 other infants died a SIDS (272120)-like death.


.0009   SUDDEN INFANT DEATH SYNDROME

MTTL1, 3290T-C
SNP: rs199474665, ClinVar: RCV000010220, RCV000850710

Opdal et al. (1999) investigated the MTTL1 gene and the first part of the MTND1 gene (516000) in 158 cases of sudden infant death syndrome (SIDS; 272120) and 97 controls. The basepairs in the range of 3230 to 3330 were investigated using PCR and temporal temperature gradient electrophoresis (TTGE). If a band shift was detected by TTGE, the area was investigated and the D-loop was sequenced. Three different point mutations (3290T-C in the MTTL1 gene, and 3308T-C (516000.0007) and 3308T-G (516000.0008)in the MTND1 gene) were detected in 4 of the SIDS cases, while none of the controls was mutated. They also found a high D-loop substitution rate in these 4 cases. Opdal et al. (1999) suggested that the findings indicated that mtDNA mutations may play a role in some cases of SIDS. They pointed out that a 3250T-C mutation in the MTTL1 gene (590050.0008) had been detected in a family in which a sister of the proband and a maternal uncle died of SIDS, and that a 3303C-T mutation in the MTTL1 gene (590050.0004) had been detected in a family in which an older brother of the proband died of SIDS.


.0010   NEUROPSYCHIATRIC DISORDER AND EARLY-ONSET CATARACT

MTTL1, 3274A-G
SNP: rs199474666, ClinVar: RCV000010221, RCV000850703, RCV002288480

Jaksch et al. (2001) reported a patient with a novel heteroplasmic 3274A-G mutation in the MTTL1 gene, who suffered from a neuropsychiatric disorder and early-onset cataract associated with severe deficiency of respiratory complex I in skeletal muscle. The patient was normal until age 12, when his performance in school declined. At age 27, he developed acute psychotic symptoms, depression, and suicidal thoughts. Bilateral hearing loss, gait instability, and bilateral dysdiadochokinesis were also noted. At that time, brain MRI showed cerebral and cerebellar atrophy and ventricular enlargement. Bilateral cataracts were found at age 30. At age 33 bilateral vision loss and tapetoretinal degeneration were noted. Changes on brain MRI were progressive. The heteroplasmic 3274A-G mutation was found in skeletal muscle (25%) but not in white blood cells of the patient.


.0011   RECLASSIFIED - VARIANT OF UNKNOWN SIGNIFICANCE

MTTL1, 3249G-A
SNP: rs199474667, ClinVar: RCV000010222

This variant, formerly titled KEARNS-SAYRE SYNDROME, has been reclassified as a variant of unknown signficance because its pathogenicity has not been confirmed.

Seneca et al. (2001) reported a male patient with clinical signs suggestive of Kearns-Sayre syndrome (530000), including onset at age 22 years of progressive visual failure with retinopathy, external ophthalmoplegia, sensorineural hearing loss, exercise intolerance, muscle weakness, and difficulty swallowing. Skeletal muscle analysis showed decreased activity of complex I and numerous ragged-red fibers. A heteroplasmic 3249G-A point mutation was found in the MTTL1 gene, with a high percentage of mutant mtDNA in skeletal muscle (85%) and in leukocytes (45%). The patient's mother carried less than 5% mutant mtDNA in her blood.

Yakubovskaya et al. (2010) found that 3249G formed a double hydrogen bond with arg387 of MTERF1 (602318). The 3249G-A mutation eliminated this interaction and significantly interfered with transcriptional termination by MTERF1.


.0012   MYELODYSPLASTIC SYNDROME, SOMATIC

MTTL1, 3242G-A
SNP: rs193303018, ClinVar: RCV000010223, RCV000850687

Ultrastructural abnormalities seen in mitochondria of bone marrow cells of patients with myelodysplastic syndrome (MDS), such as pathologic iron accumulation in the mitochondria of erythroblasts, suggest that mitochondrial dysfunction may contribute to the pathophysiology of MDS. In a 65-year-old male patient with refractory anemia with excess blasts (RAEB), Gattermann et al. (2004) identified a novel somatic mutation of the mitochondrial MTTL1 gene, 3242G-A. Heteroduplex analysis indicated that 40 to 50% of mitochondrial DNA molecules in the bone marrow carried the mutation. The mutation was not detectable by heteroduplex analysis in the peripheral blood. However, peripheral blood CD34+ cells showed the mutation with a proportion of approximately 50%. In hematopoietic colony assays, CD34+ cells from bone marrow and peripheral blood yielded only colonies with wildtype mtDNA; this result indicated that the mtDNA mutation in CD34+ cells was associated with a maturation defect. Mitochondrial tRNA mutations impair mitochondrial protein synthesis, thereby causing dysfunction of the mitochondrial respiratory chain. Gattermann et al. (2004) suggested that this effect contributed to ineffective hematopoiesis in the patient.

Yakubovskaya et al. (2010) found that 3242G interacted with arg251 of MTERF1 (602318) and that the 3242G-A mutation profoundly reduced transcriptional termination by MTERF1.


REFERENCES

  1. Aggarwal, P., Gill-Randall, R., Wheatley, T., Buchalter, M. B., Metcalfe, J., Alcolado, J. C. Identification of mtDNA mutation in a pedigree with gestational diabetes, deafness, Wolff-Parkinson-White syndrome and placenta accreta. Hum. Hered. 51: 114-116, 2001. [PubMed: 11096278] [Full Text: https://doi.org/10.1159/000022950]

  2. Bohm, M., Pronicka, E., Karczmarewicz, E., Pronicki, M., Piekutowska-Abramczuk, D., Sykut-Cegielska, J., Mierzewska, H., Hansikova, H., Vesela, K., Tesarova, M., Houstkova, H., Houstek, J., Zeman, J. Retrospective, multicentric study of 180 children with cytochrome c oxidase deficiency. Pediat. Res. 59: 21-26, 2006. [PubMed: 16326995] [Full Text: https://doi.org/10.1203/01.pdr.0000190572.68191.13]

  3. Borner, G. V., Zeviani, M., Tiranti, V., Carrara, F., Hoffmann, S., Gerbitz, K. D., Lochmuller, H., Pongratz, D., Klopstock, T., Melberg, A., Holme, E., Paabo, S. Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients. Hum. Molec. Genet. 9: 467-475, 2000. [PubMed: 10699170] [Full Text: https://doi.org/10.1093/hmg/9.4.467]

  4. Bruno, C., Kirby, D. M., Koga, Y., Garavaglia, B., Duran, G., Santorelli, F. M., Shield, L. K., Xia, W., Shanske, S., Goldstein, J. D., Iwanaga, R., Akita, Y., Carrara, F., Davis, A., Zeviani, M., Thorburn, D. R., DiMauro, S. The mitochondrial DNA C3303T mutation can cause cardiomyopathy and/or skeletal myopathy. J. Pediat. 135: 197-202, 1999. [PubMed: 10431114] [Full Text: https://doi.org/10.1016/s0022-3476(99)70022-3]

  5. Chinnery, P. F., Howell, N., Lightowlers, R. N., Turnbull, D. M. MELAS and MERRF: the relationship between maternal mutation load and the frequency of clinically affected offspring. Brain 121: 1889-1894, 1998. [PubMed: 9798744] [Full Text: https://doi.org/10.1093/brain/121.10.1889]

  6. Chinnery, P. F., Taylor, D. J., Manners, D., Styles, P., Lodi, R. No correlation between muscle A3243G mutation load and mitochondrial function in vivo. Neurology 56: 1101-1104, 2001. [PubMed: 11320187] [Full Text: https://doi.org/10.1212/wnl.56.8.1101]

  7. Chomyn, A., Enriquez, J. A., Micol, V., Fernandez-Silva, P., Attardi, G. The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNA-leu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes. J. Biol. Chem. 275: 19198-19209, 2000. [PubMed: 10858457] [Full Text: https://doi.org/10.1074/jbc.M908734199]

  8. Chuang, L.-M., Wu, H.-P., Chiu, K. C., Lai, C.-S., Tai, T.-Y., Lin, B. J. Mitochondrial gene mutations in familial non-insulin-dependent diabetes mellitus in Taiwan. Clin. Genet. 48: 251-254, 1995. [PubMed: 8825603] [Full Text: https://doi.org/10.1111/j.1399-0004.1995.tb04099.x]

  9. Ciafaloni, E., Ricci, E., Shanske, S., Moraes, C. T., Silvestri, G., Hirano, M., Simonetti, S., Angelini, C., Donati, M. A., Garcia, C., Martinuzzi, A., Mosewich, R., Servidei, S., Zammarchi, E., Bonilla, E., DeVivo, D. C., Rowland, L. P., Schon, E. A., DiMauro, S. MELAS: clinical features, biochemistry, and molecular genetics. Ann. Neurol. 31: 391-398, 1992. [PubMed: 1586140] [Full Text: https://doi.org/10.1002/ana.410310408]

  10. Costello, D. J., Sims, K. B. Efficacy of lamotrigine in disabling myoclonus in a patient with an mtDNA A3243G mutation. Neurology 72: 1279-1280, 2009. [PubMed: 19349610] [Full Text: https://doi.org/10.1212/01.wnl.0000345663.71421.1d]

  11. Damian, M. S., Seibel, P., Schachenmayr, W., Reichmann, H., Dorndorf, W. VACTERL with the mitochondrial NP 3243 point mutation. Am. J. Med. Genet. 62: 398-403, 1996. [PubMed: 8723071] [Full Text: https://doi.org/10.1002/(SICI)1096-8628(19960424)62:4<398::AID-AJMG13>3.0.CO;2-J]

  12. Dashe, J. F., Boyer, P. J. A 13-year-old girl with a relapsing-remitting neurologic disorder (CPC). New Eng. J. Med. 339: 1914-1923, 1998. [PubMed: 9874606] [Full Text: https://doi.org/10.1056/NEJM199812243392608]

  13. De Kremer, R. D., Paschini-Capra, A., Bacman, S., Argarana, C., Civallero, G., Kelley, R. I., Guelbert, N., Latini, A., de Halac, I. N., Giner-Ayala, A., Johnston, J., Proujansky, R., Gonzalez, I., Depetris-Boldini, C., Oller-Ramirez, A., Angaroni, C., Theaux, R. A., Hliba, E., Juaneda, E. Barth's syndrome-like disorder: a new phenotype with a maternally inherited A3243G substitution of mitochondrial DNA (MELAS mutation). Am. J. Med. Genet. 99: 83-93, 2001. [PubMed: 11241464] [Full Text: https://doi.org/10.1002/1096-8628(2001)9999:9999<::aid-ajmg1136>3.0.co;2-x]

  14. de Vries, D., de Wijs, I., Ruitenbeek, W., Begeer, J., Smit, P., Bentlage, H., van Oost, B. Extreme variability of clinical symptoms among sibs in a MELAS family correlated with heteroplasmy for the mitochondrial A324G mutation. J. Neurol. Sci. 124: 77-82, 1994. [PubMed: 7931425] [Full Text: https://doi.org/10.1016/0022-510x(94)90014-0]

  15. Deschauer, M., Muller, T., Wieser, T., Schulte-Mattler, W., Kornhuber, M., Zierz, S. Hearing impairment is common in various phenotypes of the mitochondrial DNA A3243G mutation. Arch. Neurol. 58: 1885-1888, 2001. [PubMed: 11708999] [Full Text: https://doi.org/10.1001/archneur.58.11.1885]

  16. Deschauer, M., Wieser, T., Neudecker, S., Lindner, A., Zierz, S. Mitochondrial 3243 A-to-G mutation (MELAS mutation) associated with painful muscle stiffness. Neuromusc. Disord. 9: 305-307, 1999. [PubMed: 10407850] [Full Text: https://doi.org/10.1016/s0960-8966(99)00019-x]

  17. Donovan, L. E., Severin, N. E. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J. Clin. Endocr. Metab. 91: 4737-4742, 2006. [PubMed: 17018649] [Full Text: https://doi.org/10.1210/jc.2006-1498]

  18. Durham, S. E., Samuels, D. C., Cree, L. M., Chinnery, P. F. Normal levels of wild-type mitochondrial DNA maintain cytochrome c oxidase activity for two pathogenic mitochondrial DNA mutations but not for m.3243A-G. Am. J. Hum. Genet. 81: 189-195, 2007. [PubMed: 17564976] [Full Text: https://doi.org/10.1086/518901]

  19. Dvorakova, V., Kolarova, H., Magner, M., Tesarova, M., Hansikova, H., Zeman, J., Honzik, T. The phenotypic spectrum of fifty Czech m.3243A-G carriers. Molec. Genet. Metab. 118: 288-295, 2016. [PubMed: 27296531] [Full Text: https://doi.org/10.1016/j.ymgme.2016.06.003]

  20. Elliott, H. R., Samuels, D. C., Eden, J. A., Relton, C. L., Chinnery, P. F. Pathogenic mitochondrial DNA mutations are common in the general population. Am. J. Hum. Genet. 83: 254-260, 2008. [PubMed: 18674747] [Full Text: https://doi.org/10.1016/j.ajhg.2008.07.004]

  21. Enter, C., Muller-Hocker, J., Zierz, S., Kurlemann, G., Pongratz, D., Forster, C., Obermaier-Kusser, B., Gerbitz, K.-D. A specific point mutation in the mitochondrial genome of Caucasians with MELAS. Hum. Genet. 88: 233-236, 1991. [PubMed: 1684568] [Full Text: https://doi.org/10.1007/BF00206080]

  22. Feigenbaum, A., Chitayat, D., Robinson, B., MacGregor, D., Myint, T., Arbus, G., Nowaczyk, M. J. M. The expanding clinical phenotype of the tRNA-leu(UUR) A-to-G mutation at np 3243 of mitochondrial DNA: diabetic embryopathy associated with mitochondrial cytopathy. Am. J. Med. Genet. 62: 404-409, 1996. [PubMed: 8723072] [Full Text: https://doi.org/10.1002/(SICI)1096-8628(19960424)62:4<404::AID-AJMG14>3.0.CO;2-S]

  23. Gattermann, N., Wulfert, M., Junge, B., Germing, U., Haas, R., Hofhaus, G. Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome. Blood 103: 1499-1502, 2004. [PubMed: 14576046] [Full Text: https://doi.org/10.1182/blood-2003-07-2446]

  24. Goto, Y., Nonaka, I., Horai, S. A mutation in the tRNA-leu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348: 651-653, 1990. [PubMed: 2102678] [Full Text: https://doi.org/10.1038/348651a0]

  25. Goto, Y., Nonaka, I., Horai, S. A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Biochim. Biophys. Acta 1097: 238-240, 1991. [PubMed: 1932147] [Full Text: https://doi.org/10.1016/0925-4439(91)90042-8]

  26. Goto, Y., Tojo, M., Tohyama, J., Horai, S., Nonaka, I. A novel point mutation in the mitochondrial tRNA-Leu(UUR) gene in a family with mitochondrial myopathy. Ann. Neurol. 31: 672-675, 1992. [PubMed: 1514779] [Full Text: https://doi.org/10.1002/ana.410310617]

  27. Hayashi, J.-I., Ohta, S., Takai, D., Miyabayashi, S., Sakuta, R., Goto, Y., Nonaka, I. Accumulation of mtDNA with a mutation at position 3271 in tRNA-leu(UUR) gene introduced from a MELAS patient to HeLa cells lacking mtDNA results in progressive inhibition of mitochondrial respiratory function. Biochem. Biophys. Res. Commun. 197: 1049-1055, 1993. [PubMed: 8280119] [Full Text: https://doi.org/10.1006/bbrc.1993.2584]

  28. Hirai, M., Suzuki, S., Onoda, M., Hinokio, Y., Hirai, A., Ohtomo, M., Chiba, M., Kasuga, S., Hirai, S., Satoh, Y., Akai, H., Miyabayashi, S., Toyota, T. Mitochondrial deoxyribonucleic acid 3256C-T mutation in a Japanese family with noninsulin-dependent diabetes mellitus. J. Clin. Endocr. Metab. 83: 992-994, 1998. [PubMed: 9506761] [Full Text: https://doi.org/10.1210/jcem.83.3.4643]

  29. Houshmand, M., Larsson, N.-G., Oldfors, A., Tulinius, M., Holme, E. Fatal mitochondrial myopathy, lactic acidosis, and complex I deficiency associated with a heteroplasmic A-to-G mutation at position 3251 in the mitochondrial tRNA-leu(UUR) gene. Hum. Genet. 97: 269-273, 1996. [PubMed: 8786060] [Full Text: https://doi.org/10.1007/BF02185750]

  30. Jaksch, M., Lochmuller, H., Schmitt, F., Volpel, B., Obermaier-Kusser, B., Horvath, R. A mutation in mt tRNAleu(UUR) causing a neuropsychiatric syndrome with depression and cataract. Neurology 57: 1930-1931, 2001. [PubMed: 11723298] [Full Text: https://doi.org/10.1212/wnl.57.10.1930]

  31. Janssen, A. J. M., Schuelke, M., Smeitink, J. A. M., Trijbels, F. J. M., Sengers, R. C. A., Lucke, B., Wintjes, L. T. M., Morava, E., van Engelen, B. G. M., Smits, B. W., Hol, F. A., Siers, M. H., ter Laak, H., van der Knaap, M. S., van Spronsen, F. J., Rodenburg, R. J. T., van den Heuvel, L. P. Muscle 3243A-G mutation load and capacity of the mitochondrial energy-generating system. Ann. Neurol. 63: 473-481, 2008. [PubMed: 18306232] [Full Text: https://doi.org/10.1002/ana.21328]

  32. Janssen, G. M. C., Hensbergen, P. J., van Bussel, F. J., Balog, C. I. A., Maassen, J. A., Deelder, A. M., Raap, A. K. The A3243G tRNA(Leu(UUR)) mutation induces mitochondrial dysfunction and variable disease expression without dominant negative acting translational defects in complex IV subunits at UUR codons. Hum. Molec. Genet. 16: 2472-2481, 2007. [PubMed: 17656376] [Full Text: https://doi.org/10.1093/hmg/ddm203]

  33. Janssen, G. M. C., Maassen, J. A., van den Ouweland, J. M. W. The diabetes-associated 3243 mutation in the mitochondrial tRNA-Leu(UUR) gene causes severe mitochondrial dysfunction without a strong decrease in protein synthesis rate. J. Biol. Chem. 274: 29744-29748, 1999. [PubMed: 10514449] [Full Text: https://doi.org/10.1074/jbc.274.42.29744]

  34. Jeppesen, T. D., Schwartz, M., Frederiksen, A. L., Wibrand, F., Olsen, D. B., Vissing, J. Muscle phenotype and mutation load in 51 persons with the 3243A-G mitochondrial DNA mutation. Arch. Neurol. 63: 1701-1706, 2006. [PubMed: 17172609] [Full Text: https://doi.org/10.1001/archneur.63.12.1701]

  35. Jones, M., Mitchell, P., Wang, J. J., Sue, C. MELAS A3243G mitochondrial DNA mutation and age related maculopathy. Am. J. Ophthal. 138: 1051-1053, 2004. [PubMed: 15629304] [Full Text: https://doi.org/10.1016/j.ajo.2004.06.026]

  36. Kaufmann, P., Engelstad, K., Wei, Y., Kulikova, R., Oskoui, M., Battista, V., Koenigsberger, D. Y., Pascual, J. M., Sano, M., Hirano, M., DiMauro, S., Shungu, D. C., Mao, X., De Vivo, D. C. Protean phenotypic features of the A3243G mitochondrial DNA mutation. Arch. Neurol. 66: 85-91, 2009. [PubMed: 19139304] [Full Text: https://doi.org/10.1001/archneurol.2008.526]

  37. Kirino, Y., Yasukawa, T., Ohta, S., Akira, S., Ishihara, K., Watanabe, K., Suzuki, T. Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease. Proc. Nat. Acad. Sci. 101: 15070-15075, 2004. [PubMed: 15477592] [Full Text: https://doi.org/10.1073/pnas.0405173101]

  38. Kobayashi, Y., Momoi, M. Y., Tominaga, K., Momoi, T., Nihei, K., Yanagisawa, M., Kagawa, Y., Ohta, S. A point mutation in the mitochondrial tRNA-leu (UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). Biochem. Biophys. Res. Commun. 173: 816-822, 1990. [PubMed: 2268345] [Full Text: https://doi.org/10.1016/s0006-291x(05)80860-5]

  39. Kobayashi, Y., Momoi, M. Y., Tominaga, K., Shimoizumi, H., Nihei, K., Yanagisawa, M., Kagawa, Y., Ohta, S. Respiration-deficient cells are caused by a single point mutation in the mitochondrial tRNA-leu (UUR) gene in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Am. J. Hum. Genet. 49: 590-599, 1991. [PubMed: 1715668]

  40. Lam, C. W., Lau, C. H., Williams, J. C., Chan, Y. W., Wong, L. J. C. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Europ. J. Pediat. 156: 562-564, 1997. [PubMed: 9243242] [Full Text: https://doi.org/10.1007/s004310050663]

  41. Latkany, P., Ciulla, T. A., Cucchillo, P., Malkoff, M. D. Mitochondrial maculopathy: geographic atrophy of the macula in the MELAS associated A to G 3243 mitochondrial DNA point mutation. Am. J. Ophthal. 128: 112-114, 1999. [PubMed: 10482110] [Full Text: https://doi.org/10.1016/s0002-9394(99)00057-4]

  42. Lertrit, P., Noer, A. S., Jean-Francois, M. J. B., Kapsa, R., Dennett, X., Thyagarajan, D., Lethlean, K., Byrne, E., Marzuki, S. A new disease-related mutation for mitochondrial encephalopathy lactic acidosis and strokelike episodes (MELAS) syndrome affects the ND4 subunit of the respiratory complex I. Am. J. Hum. Genet. 51: 457-468, 1992. [PubMed: 1323207]

  43. Li, R., Guan, M.-X. Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the tRNA(Leu(UUR)) A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes. Molec. Cell. Biol. 30: 2147-2154, 2010. Note: Erratum: Molec. Cell. Biol. 37: e00335-17, 2017. [PubMed: 20194621] [Full Text: https://doi.org/10.1128/MCB.01614-09]

  44. Majamaa, K., Moilanen, J. S., Uimonen, S., Remes, A. M., Salmela, P. I., Karppa, M., Majamaa-Voltti, K. A. M., Rusanen, H., Sorri, M., Peuhkurinen, K. J., Hassinen, I. E. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am. J. Hum. Genet. 63: 447-454, 1998. [PubMed: 9683591] [Full Text: https://doi.org/10.1086/301959]

  45. Malfatti, E., Laforet, P., Jardel, C., Stojkovic, T., Behin, A., Eymard, B., Lombes, A., Benmalek, A., Becane, H.-M., Berber, N., Meune, C., Duboc, D., Wahbi, K. High risk of severe cardiac adverse events in patients with mitochondrial m.3243A-G mutation. Neurology 80: 100-105, 2013. [PubMed: 23243073] [Full Text: https://doi.org/10.1212/WNL.0b013e31827b1a2f]

  46. Manouvrier, S., Rotig, A., Hannebique, G., Gheerbrandt, J.-D., Royer-Legrain, G., Munnich, A., Parent, M., Grunfeld, J.-P., Largilliere, C., Lombes, A., Bonnefont, J.-P. Point mutation of the mitochondrial tRNA(leu) gene (A 3243 G) in maternally inherited hypertrophic cardiomyopathy, diabetes mellitus, renal failure, and sensorineural deafness. J. Med. Genet. 32: 654-656, 1995. [PubMed: 7473662] [Full Text: https://doi.org/10.1136/jmg.32.8.654]

  47. Mariotti, C., Tiranti, V., Carrara, F., Dallapiccola, B., DiDonato, S., Zeviani, M. Defective respiratory capacity and mitochondrial protein synthesis in transformant cybrids harboring the tRNA-leu(UUR) mutation associated with maternally inherited myopathy and cardiomyopathy. J. Clin. Invest. 93: 1102-1107, 1994. [PubMed: 8132749] [Full Text: https://doi.org/10.1172/JCI117061]

  48. Matthews, P. M., Brown, R. M., Morten, K., Marchington, D., Poulton, J., Brown, G. Intracellular heteroplasmy for disease-associated point mutations in mtDNA: implications for disease expression and evidence for mitotic segregation of heteroplasmic units of mtDNA. Hum. Genet. 96: 261-268, 1995. [PubMed: 7649539] [Full Text: https://doi.org/10.1007/BF00210404]

  49. Matthews, P. M., Hopkin, J., Brown, R. M., Stephenson, J. B. P., Hilton-Jones, D., Brown, G. K. Comparison of the relative levels of the 3243 (A-to-G) mtDNA mutation in heteroplasmic adult and fetal tissues. J. Med. Genet. 31: 41-44, 1994. [PubMed: 8151636] [Full Text: https://doi.org/10.1136/jmg.31.1.41]

  50. Moilanen, J. S., Majamaa, K. Relative fitness of carriers of the mitochondrial DNA mutation 3243A-G. Europ. J. Hum. Genet. 9: 59-62, 2001. [PubMed: 11175302] [Full Text: https://doi.org/10.1038/sj.ejhg.5200550]

  51. Moraes, C. T., Ciacci, F., Bonilla, E., Jansen, C., Hirano, M., Rao, N., Lovelace, R. E., Rowland, L. P., Schon, E. A., DiMauro, S. Two novel pathogenic mitochondrial DNA mutations affecting organelle number and protein synthesis: is the tRNA-leu(UUR) gene an etiologic hot spot? J. Clin. Invest. 92: 2906-2915, 1993. [PubMed: 8254046] [Full Text: https://doi.org/10.1172/JCI116913]

  52. Moraes, C. T., Ricci, E., Bonilla, E., DiMauro, S., Schon, E. A. The mitochondrial tRNA-leu(UUR) mutation in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS): genetic, biochemical, and morphological correlations in skeletal muscle. Am. J. Hum. Genet. 50: 934-949, 1992. [PubMed: 1315123]

  53. Morten, K. J., Cooper, J. M., Brown, G. K., Lake, B. D., Pike, D., Poulton, J. A new point mutation associated with mitochondrial encephalomyopathy. Hum. Molec. Genet. 2: 2081-2087, 1993. [PubMed: 8111377] [Full Text: https://doi.org/10.1093/hmg/2.12.2081]

  54. Morten, K. J., Poulton, J., Sykes, B. Multiple independent occurrence of the 3243 mutation in mitochondrial tRNA-leu(UUR) in patients with the MELAS phenotype. Hum. Molec. Genet. 4: 1689-1691, 1995. [PubMed: 8541865] [Full Text: https://doi.org/10.1093/hmg/4.9.1689]

  55. Mosewich, R. K., Donat, J. R., DiMauro, S., Ciafaloni, E., Shanske, S., Erasmus, M., George, D. The syndrome of mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes presenting without stroke. Arch. Neurol. 50: 275-278, 1993. [PubMed: 8442706] [Full Text: https://doi.org/10.1001/archneur.1993.00540030041012]

  56. Nagata, H., Kumahara, K., Tomemori, T., Arimoto, Y., Isoyama, K., Yoshida, K., Konno, A. Frequency and clinical features of patients with sensorineural hearing loss associated with the A3243G mutation of the mitochondrial DNA in otorhinolaryngic clinics. J. Hum. Genet. 46: 595-599, 2001. [PubMed: 11587074] [Full Text: https://doi.org/10.1007/s100380170027]

  57. Nakamura, M., Yabe, I., Sudo, A., Hosoki, K., Yaguchi, H., Saitoh, S., Sasaki, H. MERRF/MELAS overlap syndrome: a double pathogenic mutation in mitochondrial tRNA genes. J. Med. Genet. 47: 659-664, 2010. [PubMed: 20610441] [Full Text: https://doi.org/10.1136/jmg.2009.072058]

  58. Nam, S.-C., Kang, C. DNA light-strand preferential recognition of human mitochondria transcription termination factor mTERF. J. Biochem. Molec. Biol. 38: 690-694, 2005. [PubMed: 16336784] [Full Text: https://doi.org/10.5483/bmbrep.2005.38.6.690]

  59. Odawara, M., Sasaki, K., Yamashita, K. Prevalence and clinical characterization of Japanese diabetes mellitus with an A-to-G mutation at nucleotide 3243 of the mitochondrial tRNA-leu(UUR) gene. J. Clin. Endocr. Metab. 80: 1290-1294, 1995. [PubMed: 7714102] [Full Text: https://doi.org/10.1210/jcem.80.4.7714102]

  60. Ogle, R. F., Christodoulou, J., Fagan, E., Blok, R. B., Kirby, D. M., Seller, K. L., Dahl, H.-H. M, Thorburn, D. R. Mitochondrial myopathy with tRNA-Leu(UUR) mutation and complex I deficiency responsive to riboflavin. J. Pediat. 130: 138-145, 1997. [PubMed: 9003864] [Full Text: https://doi.org/10.1016/s0022-3476(97)70323-8]

  61. Olsson, C., Johnsen, E., Nilsson, M., Wilander, E., Syvanen, A.-C., Lagerstrom-Fermer, M. The level of mitochondrial mutation A3243G decreases upon ageing in epithelial cells from individuals with diabetes and deafness. Europ. J. Hum. Genet. 9: 917-921, 2001. [PubMed: 11840193] [Full Text: https://doi.org/10.1038/sj.ejhg.5200742]

  62. Opdal, S. H., Rognum, T. O., Torgersen, H., Vege, A. Mitochondrial DNA point mutations detected in four cases of sudden infant death syndrome. Acta Paediat. 88: 957-960, 1999. [PubMed: 10519336] [Full Text: https://doi.org/10.1080/08035259950168441]

  63. Parsons, T., Weimer, L., Engelstad, K., Linker, A., Battista, V., Wei, Y., Hirano, M., Dimauro, S., De Vivo, D. C., Kaufmann, P. Autonomic symptoms in carriers of the m.3243A-G mitochondrial DNA mutation. Arch. Neurol. 67: 976-979, 2010. [PubMed: 20697048] [Full Text: https://doi.org/10.1001/archneurol.2010.174]

  64. Petruzzella, V., Zoccolella, S., Amati, A., Torraco, A., Lamberti, P., Carnicella, F., Serlenga, L., Papa, S. Cerebellar ataxia as atypical manifestation of the 3243A-G MELAS function. (Letter) Clin. Genet. 65: 64-65, 2004. [PubMed: 15032978] [Full Text: https://doi.org/10.1111/j..2004.00185.x]

  65. Pyle, A., Taylor, R. W., Durham, S. E., Deschauer, M., Schaefer, A. M., Samuels, D. C., Chinnery, P. F. Depletion of mitochondrial DNA in leucocytes harbouring the 3243A-G mtDNA mutation. (Letter) J. Med. Genet. 44: 69-74, 2007. [PubMed: 16950816] [Full Text: https://doi.org/10.1136/jmg.2006.043109]

  66. Rahman, S., Poulton, J., Marchington, D., Suomalainen, A. Decrease of 3243 A-G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. Am. J. Hum. Genet. 68: 238-240, 2001. [PubMed: 11085913] [Full Text: https://doi.org/10.1086/316930]

  67. Rajasimha, H. K., Chinnery, P. F., Samuels, D. C. Selection against pathogenic mtDNA mutations in a stem cell population leads to the loss of the 3243A-G mutation in blood. Am. J. Hum. Genet. 82: 333-343, 2008. [PubMed: 18252214] [Full Text: https://doi.org/10.1016/j.ajhg.2007.10.007]

  68. Reardon, W., Ross, R. J. M., Sweeney, M. G., Luxon, L. M., Pembrey, M. E., Harding, A. E., Trembath, R. C. Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA. Lancet 340: 1376-1379, 1992. [PubMed: 1360090] [Full Text: https://doi.org/10.1016/0140-6736(92)92560-3]

  69. Salpietro, C. D., Briuglia, S., Merlino, M. V., Di Bella, C., Rigoli, L. A mitochondrial DNA mutation (A3243G mtDNA) in a family with cyclic vomiting. Europ. J. Pediat. 162: 727-728, 2003. [PubMed: 12905015] [Full Text: https://doi.org/10.1007/s00431-003-1280-1]

  70. Sasarman, F., Antonicka, H., Shoubridge, E. A. The A3243G tRNALeu(UUR) MELAS mutation causes amino acid misincorporation and a combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2. Hum. Molec. Genet. 17: 3697-3707, 2008. [PubMed: 18753147] [Full Text: https://doi.org/10.1093/hmg/ddn265]

  71. Schulz, J. B., Klockgether, T., Dichgans, J., Seibel, P., Reichmann, H. Mitochondrial gene mutations and diabetes mellitus. (Letter) Lancet 341: 438-439, 1993. [PubMed: 8094200]

  72. Seneca, S., Verhelst, H., de Meirleir, L., Meire, F., Ceuterick-de Groote, C., Lissens, W., van Coster, R. A new mitochondrial point mutation in the transfer RNA-leu gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome. Arch. Neurol. 58: 1113-1118, 2001. [PubMed: 11448301] [Full Text: https://doi.org/10.1001/archneur.58.7.1113]

  73. Silvestri, G., Santorelli, F. M., Shanske, S., Whitley, C. B., Schimmenti, L. A., Smith, S. A., DiMauro, S. A new mtDNA mutation in the tRNA-leu(UUR) gene associated with maternally inherited cardiomyopathy. Hum. Mutat. 3: 37-43, 1994. [PubMed: 7906985] [Full Text: https://doi.org/10.1002/humu.1380030107]

  74. Smith, P. R., Bain, S. C., Good, P. A., Hattersley, A. T., Barnett, A. H., Gibson, J. M., Dodson, P. M. Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness caused by the mitochondrial DNA 3243 tRNA(leu) A-to-G mutation. Ophthalmology 106: 1101-1108, 1999. [PubMed: 10366077] [Full Text: https://doi.org/10.1016/S0161-6420(99)90244-0]

  75. Stenqvist, L., Paetau, A., Valanne, L., Suomalainen, A., Pihko, H. A juvenile case of MELAS with T3271C mitochondrial DNA mutation. Pediat. Res. 58: 258-262, 2005. [PubMed: 16006433] [Full Text: https://doi.org/10.1203/01.PDR.0000169966.82325.1A]

  76. Stone, D. L., Biesecker, L. G. Mitochondrial NP 3243 point mutation is not a common cause of VACTERL association. (Letter) Am. J. Med. Genet. 72: 237-238, 1997. [PubMed: 9382149]

  77. Sue, C. M., Bruno, C., Andreu, A. L., Cargan, A., Mendell, J. R., Tsao, C.-Y., Luquette, M., Paolicchi, J., Shanske, S., DiMauro, S., De Vivo, D. C. Infantile encephalopathy associated with the MELAS A3243G mutation. J. Pediat. 134: 696-700, 1999. [PubMed: 10356136] [Full Text: https://doi.org/10.1016/s0022-3476(99)70283-0]

  78. Sweeney, M. G., Bundey, S., Brockington, M., Poulton, K. R., Winer, J. B., Harding, A. E. Mitochondrial myopathy associated with sudden death in young adults and a novel mutation in the mitochondrial DNA leucine transfer RNA(UUR) gene. Quart. J. Med. 86: 709-713, 1993. [PubMed: 8265770]

  79. Tamagawa, Y., Kitamura, K., Hagiwara, H., Ishida, T., Nishizawa, M., Saito, T., Iwamoto, Y. Audiologic findings in patients with a point mutation at nucleotide 3,243 of mitochondrial DNA. Ann. Otol. Rhinol. Laryng. 106: 338-342, 1997. [PubMed: 9109727] [Full Text: https://doi.org/10.1177/000348949710600414]

  80. Torroni, A., Campos, Y., Rengo, C., Sellitto, D., Achilli, A., Magri, C., Semino, O., Garcia, A., Jara, P., Arenas, J., Scozzari, R. Mitochondrial DNA haplogroups do not play a role in the variable phenotypic presentation of the A3243G mutation. Am. J. Hum. Genet. 72: 1005-1012, 2003. [PubMed: 12612863] [Full Text: https://doi.org/10.1086/373936]

  81. Uimonen, S., Moilanen, J. S., Sorri, M., Hassinen, I. E., Majamaa, K. Hearing impairment in patients with 3243A-G mtDNA mutation: phenotype and rate of progression. Hum. Genet. 108: 284-289, 2001. [PubMed: 11379873] [Full Text: https://doi.org/10.1007/s004390100475]

  82. Uusimaa, J., Moilanen, J. S., Vainionpaa, L., Tapanainen, P., Lindholm, P., Nuutinen, M., Lopponen, T., Maki-Torkko, E., Rantala, H., Majamaa, K. Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A-G mutation in children. Ann. Neurol. 62: 278-287, 2007. [PubMed: 17823937] [Full Text: https://doi.org/10.1002/ana.21196]

  83. van den Ouweland, J. M. W., Lemkes, H. H. P. J., Ruitenbeek, W., Sandkuijl, L. A., de Vijlder, M. F., Struyvenberg, P. A. A., van de Kamp, J. J. P., Maassen, J. A. Mutation in mitochondrial tRNA(leu-UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nature Genet. 1: 368-371, 1992. [PubMed: 1284550] [Full Text: https://doi.org/10.1038/ng0892-368]

  84. Velho, G., Byrne, M. M., Clement, K., Sturis, J., Pueyo, M. E., Blanche, H., Vionnet, N., Fiet, J., Passa, P., Robert, J.-J., Polonsky, K. S., Froguel, P. Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNA Leu(UUR) gene mutation. Diabetes 45: 478-487, 1996. [PubMed: 8603770] [Full Text: https://doi.org/10.2337/diab.45.4.478]

  85. Vilarinho, L., Santorelli, F. M., Rosas, M. J., Tavares, C., Melo-Pires, M., DiMauro, S. The mitochondrial A3243G mutation presenting as severe cardiomyopathy. J. Med. Genet. 34: 607-609, 1997. [PubMed: 9222976] [Full Text: https://doi.org/10.1136/jmg.34.7.607]

  86. Wilichowski, E., Korenke, G. C., Ruitenbeek, W., De Meirleir, L., Hagendorff, A., Janssen, A. J. M., Lissens, W., Hanefeld, F. Pyruvate dehydrogenase complex deficiency and altered respiratory chain function in a patient with Kearns-Sayre/MELAS overlap syndrome and A3243G mtDNA mutation. J. Neurol. Sci. 157: 206-213, 1998. [PubMed: 9619647] [Full Text: https://doi.org/10.1016/s0022-510x(98)00068-9]

  87. Yakubovskaya, E., Mejia, E., Byrnes, J., Hambardjieva, E., Garcia-Diaz, M. Helix unwinding and base flipping enable human MTERF1 to terminate mitochondrial transcription. Cell 141: 982-993, 2010. [PubMed: 20550934] [Full Text: https://doi.org/10.1016/j.cell.2010.05.018]

  88. Yang, C.-Y., Lam, H.-C., Lee, H.-C., Wei, Y.-H., Lu, C.-C., Han, T.-M., Tsai, J.-L., Chuang, Y.-H., Lee, J.-K. MELAS syndrome associated with diabetes mellitus and hyperthyroidism: a case report from Taiwan. Clin. Endocr. 43: 235-239, 1995. [PubMed: 7554321] [Full Text: https://doi.org/10.1111/j.1365-2265.1995.tb01922.x]

  89. Yasukawa, T., Suzuki, T., Suzuki, T., Ueda, T., Ohta, S., Watanabe, K. Modification defect at anticodon wobble nucleotide of mitochondrial tRNAs-Leu(UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. J. Biol. Chem. 275: 4251-4257, 2000. [PubMed: 10660592] [Full Text: https://doi.org/10.1074/jbc.275.6.4251]

  90. Yoneda, M., Chomyn, A., Martinuzzi, A., Hurko, O., Attardi, G. Marked replicative advantage of human mtDNA carrying a point mutation that causes the MELAS encephalomyopathy. Proc. Nat. Acad. Sci. 89: 11164-11168, 1992. [PubMed: 1454794] [Full Text: https://doi.org/10.1073/pnas.89.23.11164]

  91. Yorifuji, T., Kawai, M., Momoi, T., Sasaki, H., Furusho, K., Muroi, J., Shimizu, K., Takahashi, Y., Matsumura, M., Nambu, M., Okuno, T. Nephropathy and growth hormone deficiency in a patient with mitochondrial tRNA-leu(UUR) mutation. J. Med. Genet. 33: 621-622, 1996. [PubMed: 8818955] [Full Text: https://doi.org/10.1136/jmg.33.7.621]

  92. Zeviani, M., Gellera, C., Antozzi, C., Rimoldi, M., Morandi, L., Villani, F., Tiranti, V., DiDonato, S. Maternally inherited myopathy and cardiomyopathy: association with mutation in mitochondrial DNA tRNA-leu(UUR). Lancet 338: 143-147, 1991. [PubMed: 1677065] [Full Text: https://doi.org/10.1016/0140-6736(91)90136-d]

  93. Zeviani, M., Tiranti, V., Piantadosi, C. Mitochondrial disorders. Medicine 77: 59-72, 1998. [PubMed: 9465864] [Full Text: https://doi.org/10.1097/00005792-199801000-00006]


Contributors:
Ada Hamosh - updated : 12/08/2016
Cassandra L. Kniffin - updated : 12/29/2014
Patricia A. Hartz - updated : 9/19/2013
Patricia A. Hartz - updated : 4/17/2012
Cassandra L. Kniffin - updated : 1/21/2011
Cassandra L. Kniffin - updated : 11/23/2010
Cassandra L. Kniffin - updated : 8/24/2010
Cassandra L. Kniffin - updated : 11/11/2009
Cassandra L. Kniffin - updated : 9/2/2009
Cassandra L. Kniffin - updated : 4/6/2009
Cassandra L. Kniffin - updated : 3/12/2009
Ada Hamosh - updated : 9/8/2008
Cassandra L. Kniffin - updated : 4/17/2008
Cassandra L. Kniffin - updated : 1/15/2008
John A. Phillips, III - updated : 11/7/2007
Cassandra L. Kniffin - updated : 9/28/2007
Victor A. McKusick - updated : 8/8/2007
Cassandra L. Kniffin - updated : 5/30/2007
Victor A. McKusick - updated : 2/21/2007
Cassandra L. Kniffin - updated : 2/20/2006
Cassandra L. Kniffin - updated : 10/17/2005
Jane Kelly - updated : 2/28/2005
Patricia A. Hartz - updated : 1/13/2005
Jane Kelly - updated : 1/12/2005
Victor A. McKusick - updated : 4/16/2004
Victor A. McKusick - updated : 2/25/2004
Ada Hamosh - updated : 5/9/2003
Cassandra L. Kniffin - updated : 12/4/2002
Michael B. Petersen - updated : 8/20/2002
Cassandra L. Kniffin - updated : 6/4/2002
Victor A. McKusick - updated : 1/8/2002
Victor A. McKusick - updated : 12/21/2001
Victor A. McKusick - updated : 10/30/2001
Victor A. McKusick - updated : 5/7/2001
Michael B. Petersen - updated : 4/27/2001
Sonja A. Rasmussen - updated : 4/3/2001
Victor A. McKusick - updated : 2/14/2001
Victor A. McKusick - updated : 1/24/2001
Victor A. McKusick - updated : 8/31/2000
George E. Tiller - updated : 4/14/2000
Victor A. McKusick - updated : 2/1/2000
Victor A. McKusick - updated : 1/31/2000
Victor A. McKusick - updated : 12/15/1999
Victor A. McKusick - updated : 10/25/1999
Victor A. McKusick - updated : 10/13/1999
Victor A. McKusick - updated : 8/5/1999
Victor A. McKusick - updated : 2/20/1999
Victor A. McKusick - updated : 1/7/1999
Victor A. McKusick - updated : 9/11/1998
Victor A. McKusick - updated : 8/26/1998
John A. Phillips, III - updated : 8/21/1998
Victor A. McKusick - updated : 3/24/1998
Michael J. Wright - updated : 12/18/1997
Victor A. McKusick - updated : 9/5/1997
Victor A. McKusick - updated : 7/11/1997
Victor A. McKusick - updated : 6/21/1997
Iosif W. Lurie - updated : 9/17/1996

Creation Date:
Victor A. McKusick : 3/2/1993

Edit History:
carol : 10/20/2023
carol : 04/13/2023
alopez : 04/25/2022
carol : 09/11/2017
alopez : 12/08/2016
alopez : 09/23/2016
carol : 01/13/2015
mcolton : 12/29/2014
ckniffin : 12/29/2014
mgross : 9/19/2013
carol : 9/17/2013
carol : 11/12/2012
mgross : 5/14/2012
terry : 4/17/2012
carol : 6/8/2011
wwang : 2/16/2011
ckniffin : 1/21/2011
wwang : 11/29/2010
ckniffin : 11/23/2010
wwang : 9/16/2010
ckniffin : 8/24/2010
ckniffin : 8/23/2010
wwang : 12/3/2009
ckniffin : 11/11/2009
wwang : 9/9/2009
ckniffin : 9/2/2009
wwang : 4/13/2009
ckniffin : 4/6/2009
wwang : 3/24/2009
ckniffin : 3/12/2009
alopez : 9/17/2008
terry : 9/8/2008
wwang : 4/23/2008
ckniffin : 4/17/2008
wwang : 1/31/2008
ckniffin : 1/15/2008
alopez : 11/7/2007
wwang : 10/4/2007
ckniffin : 9/28/2007
alopez : 8/24/2007
terry : 8/8/2007
wwang : 6/6/2007
ckniffin : 5/30/2007
alopez : 2/26/2007
terry : 2/21/2007
carol : 2/1/2007
alopez : 1/12/2007
wwang : 3/1/2006
ckniffin : 2/20/2006
carol : 10/19/2005
ckniffin : 10/17/2005
terry : 8/3/2005
terry : 4/21/2005
terry : 4/6/2005
tkritzer : 2/28/2005
mgross : 1/13/2005
tkritzer : 1/12/2005
tkritzer : 10/15/2004
ckniffin : 7/15/2004
alopez : 4/20/2004
alopez : 4/20/2004
terry : 4/16/2004
tkritzer : 2/26/2004
terry : 2/25/2004
cwells : 5/13/2003
terry : 5/9/2003
cwells : 12/10/2002
ckniffin : 12/4/2002
alopez : 8/20/2002
carol : 6/17/2002
ckniffin : 6/4/2002
carol : 5/9/2002
carol : 1/9/2002
carol : 1/8/2002
terry : 1/8/2002
alopez : 1/8/2002
cwells : 1/3/2002
terry : 12/21/2001
carol : 11/9/2001
mcapotos : 11/7/2001
terry : 10/30/2001
mcapotos : 5/11/2001
terry : 5/7/2001
cwells : 5/4/2001
mcapotos : 5/2/2001
mcapotos : 4/27/2001
mcapotos : 4/26/2001
mcapotos : 4/3/2001
cwells : 2/20/2001
terry : 2/14/2001
cwells : 1/26/2001
terry : 1/24/2001
mcapotos : 9/5/2000
mcapotos : 8/31/2000
carol : 5/30/2000
alopez : 4/14/2000
terry : 4/14/2000
mcapotos : 2/14/2000
mcapotos : 2/8/2000
terry : 2/1/2000
carol : 1/31/2000
terry : 1/31/2000
mgross : 1/10/2000
terry : 12/15/1999
carol : 10/25/1999
carol : 10/13/1999
jlewis : 8/26/1999
terry : 8/5/1999
carol : 2/23/1999
terry : 2/20/1999
carol : 1/13/1999
terry : 1/7/1999
carol : 9/16/1998
terry : 9/11/1998
alopez : 8/31/1998
carol : 8/27/1998
terry : 8/26/1998
terry : 8/25/1998
terry : 8/21/1998
terry : 8/21/1998
terry : 8/21/1998
terry : 8/21/1998
alopez : 5/21/1998
psherman : 3/27/1998
psherman : 3/24/1998
dholmes : 3/4/1998
alopez : 1/15/1998
terry : 12/18/1997
terry : 11/11/1997
terry : 10/20/1997
terry : 9/12/1997
terry : 9/5/1997
terry : 7/11/1997
terry : 7/11/1997
terry : 6/24/1997
terry : 6/21/1997
mark : 9/25/1996
carol : 9/17/1996
terry : 8/19/1996
terry : 7/29/1996
mark : 3/4/1996
terry : 2/20/1996
mark : 1/17/1996
mark : 1/17/1996
mark : 10/15/1995
terry : 11/14/1994
carol : 9/12/1994
jason : 7/14/1994
carol : 10/18/1993
carol : 5/26/1993